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ABSTRACT OF THE DISSERTATION
The Decision Maker: Understanding the role of IFRD1 in urothelial plasticity and regeneration
By
Bisiayo E Fashemi
Doctor of Philosophy in Biology and Biomedical Sciences
Regenerative, Developmental, and Stem Cell Biology
Washington University in St. Louis, 2021
Professor Indira U Mysorekar, Chair

The bladder urothelium forms a highly specialized watertight barrier to urinary wastes. The
urothelium offers an unusual example of tissue regeneration: although urothelial cells do not
rapidly turn over under physiological conditions, they have an impressive capacity to regenerate
tissue upon injury. Even more remarkable, depending on the modality of injury (sterile, infectious)
there appear to be two distinctive modes of urothelial regeneration. We have previously shown
that in response to a urinary tract infection (UTI), the urothelial stem cell niche becomes activated
and induces rapid restoration of the urothelium, whereas, regeneration following sterile injury does
not involve stem cell activity. However, the key driver(s) of mode of regeneration choice has yet
to be elucidated.
To better understand the regulatory pathways important for tissue regenerative response,
we performed large unbiased RNA-Seq and proteomics analyses. We identified interferon-related
developmental regulator 1 (IFRD1), a transcriptional co-regulator, as a gene that is rapidly
activated upon the induction of a UTI. Ifrd1 has been shown recently to be important for
paligenosis, a process differentiated cells use to reenter the cell cycle to regenerate lost tissue.

xii

Interestingly, we observe that even in the absence of injury, loss of Ifrd1 results in gross urothelial
defects: excess vesicular congestion in terminally differentiated cells including aberrant
accumulation of mitochondria and abnormal endoplasmic reticulum (ER). Furthermore, we show
that Ifrd1 affects localization and trafficking of uroplakins, tetraspanin proteins that constitute
organized urothelial plaques, and which dimerize in the ER and assemble into heterotetramer in
the Golgi and trans-Golgi network (TGN), where they undergo chain-specific glycosylation and
proteolytic processing. Fully formed uroplakin plaques are then expressed along the apical surface
of the urothelium where they are eventually endocytosed and undergo recycling. Loss of Ifrd1
results in dysfunctional uroplakin ER-> Golgi translocation and aberrant accumulation in ER.
Proteomic analyses revealed a significant increase in the unfolded protein response (UPR) and
stress.
In agreement with this, we note an increase in the ER chaperone, Bip and the association
of IFRD1 with a number of eIF2α subunits, the critical translation initiation factor that quenches
global, cellular mRNA translation and can ultimately trigger apoptosis. Indeed, induction of injury
in the ifrd1-/- mouse results in massive epithelial exfoliation into the urine and dysregulated
recruitment of progenitor cells for regeneration. Ongoing work is elucidating the molecular
underpinnings of this response. In sum, we suggest IFRD1 plays a role in the decision-making
matrix of urothelial regeneration and that IFRD1 plays a role in urothelial plasticity.

xiii

Chapter 1: Introduction

1

1.1 The Urinary Bladder: Structure and Function
The primary function of the urinary bladder is the storage of urine. The micturition cycle,
or the process of urinating, occurs multiple times a day. A healthy normal adult bladder has the
capacity to hold 300-400 mL of fluid

1,2

. As the bladder fills with urine, it must also stretch to

accommodate the increase in volume. This change is associated with structural changes and
rearrangement of the tissue components. As the bladder voids, the tissue must once again undergo
rearrangement. Unlike any other tissue under normal physiological conditions, the bladder
undergoes constant tissue rearrangement multiple times throughout the day.
Aside from changing volume, the bladder must also store urine. Following the filtration of
blood in the kidneys, urine travels through the ureters to the bladder. Composed of water, urea,
inorganic salts, and organic compounds, the purpose of urine is to excrete waste from the body 3.
As a storage unit of urine, the bladder must provide a protective barrier between the waste and the
subcutaneous tissue of the bladder. To that end, the bladder epithelium (urothelium) provides a
both chemical and physical water-tight barrier.

1.2 Diseases of the Bladder
There are a number of conditions that can disrupt the normal function of bladder and are
associated with both a personal and financial burden

4-6

. Because there distinct differences in

anatomy, diseases afflict males and females differently. For example, bladder cancer is diagnosed
at significantly higher rates in men then in women

7,8

. However, bladder disorders such as

interstitial cystitis /bladder pain syndrome (IC/BPS), overactive bladder (OAB), and urinary tract
infections (UTIs) are more common in women. IC/BPS is a chronic pelvic pain condition that is
typically accompanied by urinary symptom(s) such as nocturia, frequency and urgency

2

9,10

. The

terms Interstitial cystitis and bladder pain syndrome are used interchangeably. While prevalence
rates vary greatly, IC/BPS is thought to afflict 850 per 100,000 women, who are typically
diagnosed over the age of 40

11,12

. OAB is characterized as urinary urgency and is usually

accompanied by frequency 13,14. It is believed around 33 million American adults suffer from OAB,
and most common in patients over the age of 40 years old 15,16. UTIs (which will be discussed at
length later), are bacterial infections of the bladder and/or kidneys. Women are particularly
susceptible to recurrent UTIs (rUTIs), which are defined as three or more UTIs during a 12-month
period 17,18. While bladder disease is common in women, the risk of diseases increases with age 1921

. Postmenopausal women are particularly susceptible to rUTIs, with 53% of women over the age

of 55 years old experiencing at least one incidence of rUTI within a year, compared to only 36%
of women under the age of 55 22.

1.3 Effects of Estrogen Deficiency on the Bladder
Estrogen deficiency has been linked to increased urogenital tract dysfunction following
menopause 23-25. Estrogen receptors can be found throughout the lower urogenital tract, including
the vagina, bladder, urethra, and the pelvic floor musculature26,27. In particular, estrogen provides
a protective role against UTIs and supports urothelial permeability 28-30. Unlike systemic hormone
replacement therapy, vaginal estrogen therapy (VET) has long been associated with overall
improvement of lower urinary tract symptoms (LUTS) 31-34. Much like the age-associated changes
to the vaginal microbiome, we are beginning to understand the similar shifting dynamics of the
urinary microbiome. While both pre- and postmenopausal women show dominance of
Lactobacillus in both the vagina and bladder, Lactobacillus has a relative abundance of 77.8% in

3

premenopausal women compared to 42.0% in postmenopausal women

35

. VET increases the

dominance of Lactobacillus in both the vagina and bladder of postmenopausal women 36-38.
Unlike traditional hormone replacement therapy, targeted VET does not readily cycle
systemically. Use of VET by postmenopausal women is effective in the reduction of rUTIs 32,36,3941

. In Chapter 4, using an aged ovariectomized mouse model, I describe the effectiveness of VET

in reducing rUTIs due to fewer quiescent intracellular reservoirs (QIRs), which can seed new
infections. Furthermore, VET decreased the expression of proinflammatory markers at baseline,
in the uninfected bladder.

Figure 1.1: The urinary tract and structures of the bladder. A) Organs of the urinary tract. B) Structure of the bladder depicting
the detrusor muscles (DM), lamina propria (LP), the bladder epithelium (E), and the lumen (L). C) The bladder epithelium, called
the urothelium. White dash separate the lamina propria from the urothelium, and red outlines superficial cells.

1.4 Functional Anatomy of the Bladder
The bladder is hollow muscular organ that sits in the pelvis of humans. There are three
main layers of the bladder, the muscularis propria, the lamina propria, and the urothelium (Figure
1.1). A functional voiding behavior in which the bladder fills and contracts, involves the interaction
of different cell types (urothelium, nerves, and detrusor muscle layer). Spontaneous urination
patterns in unrestrained mice can be used as a proxy for understanding urinary function in response
to various conditions such as sex, age and environmental changes 42-45. Void Spot Assays (VSA)
quantify the number, location, and volume of voids, and are an inexpensive tool to assess lower

4

urinary tract function 46. In Chapter 2, I summarize the effectiveness and limitations of VSA in the
study of LUTS.

Figure 1.2: Urothelial cells and their markers A) Basal cells (brown), stem cells (red), intermediate cells (orange), and superficial
cells (blue). B) Markers of the urothelium

The urothelium (Figure 1.2), which is a pseudo-stratified transitional epithelium, serves as
a protective barrier of the bladder to urine 47-51. The adult urothelium has a remarkable regenerative
capacity; when injured, urothelial cells are able to respond as fast as embryonic bladder cells 52-54.
In this chapter, I will examine the basic functions and molecular underpinnings of the urothelium
under physiological condition.
The barrier cells of the urothelium are called superficial cells (also known as umbrella cells
and P1 cells). These large (>100 microns), multinucleated, post-mitoic cells are terminally
differentiated and provide a both a physical and chemical barrier of the tissue to the hypertonic

5

urine 48. The apical membrane surface of these cells are unique, they contain luminal leaflets called
asymmetrical unit membranes (AUM). AUMs are primarily comprised of uroplakin proteins
(UPK), which are a family of transmembrane proteins that render the surface of the superficial cell
impermeable 55-57. Superficial cells are the most differentiated cells of the urothelium. A superficial
cell is terminally differentiated by the expression of uroplakin proteins (UPI-III), cytokeratin (CK)
20, and p27kip1.
Below the superficial cell layer reside the intermediate cells (also known as P2 cells), which
are in an intermediate state of differentiation and are 10-15 microns large

54

. The number of

intermediate cell layers can vary depending on species and micturition cycle, with humans having
7-8 layers, while rodents typically display one to two layers 48,53,58. While most intermediate cells
are mononucleated, a subset have been shown undergo incomplete cytokinesis, resulting in a
subpopulation of binucleated intermediate cells that eventually give rise to superficial cells
following endoreplication 59. Intermediate cells are characterized by the expression of CK7 and
P63 60. A subset of intermediate cells in direct contact with superficial cells, have also been shown
to express low levels of uroplakin protein, which rapidly increases in response injury to the
superficial cell layer 61,62.
The last cell layer of the urothelium are the basal cells (also known as P3 cells), which are
mononucleated and 5-10 microns large

48,54

. Basal cells are the least differentiated cells of the

urothelium, and characterized by the expression of CK5, Shh, and P63

63-65

. A subpopulation of

basal cells have been identified as CK14-positive stem cells, with long-term repopulating
capabilities

66

. Recent single sequencing analysis of urothelial cells revealed a novel

stem/progenitor cell marker called Abnormal Spindle Microtubule Assembly (ASPM). Similar to
CK14, the number of ASPM-positive cells under homeostasis was few, however, following

6

infectious injury to the urothelium, the number of ASPM-positive cells significantly increases in
the basal cell layer 67.

1.5 The Expression and Organization of Uroplakin Proteins in Superficial Cells
As the building blocks of urothelial plaques, four uroplakin proteins were first identified
using electron microscopy 68-70. The four major uroplakins are, the tetraspanin UPIa (27-kDa) and
UPIb (28-kDa), and the single pass UPII (15-kDa) and UPIII (47-kDa) 56,71,72. Each protein is first
synthesized as a monomer, before undergoing a complex set of glycosylations before forming the
hexagonal plaque structure. All four uroplakin proteins and their plaque formation, are highly
conserved across mammalian species 71,73. However, the differentiation of uroplakin proteins and
its presence in specific cell types, appears to differ between species of higher and lower mammals.
For example, in humans and cattle which have thicker urothelium, uroplakin proteins are primarily
found in the uppermost superficial cell layer; whereas in rodents which possess fewer layers of
urothelium, uroplakin proteins can be detected in varying degrees, within all cell types of the
urothelium 72,74-76.
Both UPIa and UPIb contain four transmembrane domains, with their sugar moieties
exposed to the lumen of the bladder
70

77,78

. They share roughly 40% of their amino acid sequence

. Murine UPIa contains one N-glycosylation site, located at Asn-169 79. This highly monosylated

site contains 5-9 terminal mannose residues, with the predominant glycovariant containing eight
terminal mannose 79. The N-glycosylation site of UPIb is located at residue Asn-131, where the
main glycovariant is a fucosylated tetra-antennary N-glycoform with 6 mannose residues 79.
The maturation of UPII is a dynamic multi-glycosylation modification process, with there
being five forms of

UPII. While a transmembrane protein, UPII contains only a single

7

transmembrane domain, which only contains a small cytoplasmic domain 68. Primarily synthesized
as a 19-kDa non glycosylated prepro-UPII precursor, UPII contains a propeptide fragment
consisting of three potential glycosylation sites 68,71,78. Following cleavage of the signal peptide in
the ER, three high-mannose glycans are added to the propeptide, forming proUPII. As proUPII
transitions into the golgi, two of the three high-mannose glycans are transformed into complex
glycans. Following transition into the trans-golgi network (TGN), the cleavage of the propeptide
containing glycosylation, is cleaved, giving rise to the mature form of UPII

56,80-82

.

The extracellular domain of UPIII contains three potential N-glycosylation sites at Asn34,
Asn74, and Asn170 that undergo the addition of N-linked glycans

69

. As the largest uroplakin

protein, UPIII is thought to contribute to the surface glycocalyx of the urothelium 69. Given the
size of the cytoplasmic domain is larger than that of UPII, UPIII is thought to anchor the fully
formed uroplakin plaque to the cytoskeleton 83. Selective UPIII ablation experiments have shown
its importance to overall bladder barrier function. While uroplakin plaques are able to form in the
urothelium of mice lacking UPIII, AUMs are smaller in size 84.
The formation of AUMs consist of a multi-step process in which individual uroplakins
dimerize before eventually forming heterotetramers. The uroplakin proteins then assembly into
16-nm particles, forming 2D hexagonal plaques that are delivered to the apical surface of the
superficial cells by discoidal and fusiform vesicles (DFVs)

85,86

. These four proteins

heterodimerize (UPIa/UPII and UPIb/UPIII) in the endoplasmic reticulum (ER), before forming
heterotetramers in the golgi and trans-golgi network 81,82. Aside from rendering the apical surface
of superficial cells impermeable, the addition of UPK plaques to the membrane aids in the physical
expansion and constriction of the bladder during voiding 87-90.

8

Many have shown the importance of individual uroplakin proteins in the formation and
function of plaques. The selective ablation of UPIII resulted in a number of abnormalities. There
was found to be increased gene expression of UPIb (which dimerizes with UPIII), but an overall
decrease in protein levels which was also associated with decreased glycosylation and trafficking
of UPIb 91. However, Tu et al (2002) revealed that of the four uroplakin proteins, UPIb is the only
protein that can successfully exit the ER without dimerizing with UPIII 92. This is due to UPIb
forming a dimer with the glycoprotein p35, which closely relates to UPIII 93. Along with forming
smaller plaques, the resulting barrier was leaky and the enlarged ureteral orifices led urine
backflow, a condition known as vesicoureteral Reflux (VUR) 91. VUR is one of the most common
congenital urological abnormalities in children, and is associated with increased (UTIs) and renal
scarring 94. Lack of UPIII also results in altered kidney function and size 95.
UPII-deficient mice have reduced protein levels of UPIa, UPIb, and UPIII; while the
mRNA levels of UPIa and UPIII were slightly upregulated, there was a 10-20-fold increase in
mRNA levels of UPIb

96

. Superficial cells of UPII knockout mice were hyperplasic, and

completely lacked apical-surface plaques

96

. These UPII-deficient superficial cells also lacked

disk-like fusiform vesicles, instead, uroplakin proteins were instead trafficked to the surface by
small spherical vesicles

96

. Similarly, to UPIII knockout bladders, these mice experience VUR,

renal failure, and hydronephrosis

96

. The increase in UPIb mRNA levels following ablation of

UPII or UPIII indicates a compensatory-role of UPIb in response to overall changes to uroplakin
protein expression.
1.6 Trafficking of Uroplakin Proteins to the Apical Surface of Superficial Cells
The apical surface of the urothelium is made up of roughly 90% of uroplakin plaques that
must be trafficked throughout the cell

90

. The maturation of uroplakin plaques is a step-wise

9

process, which occurs concurrently with the trafficking of these structures to the apical surface of
the cell. The homeostatic control and regulation of vesicle trafficking is vital to the function of the
bladder, given the importance of these structures to the integrity of superficial cells.
The apical expression of uroplakin proteins is a two-step process in which membrane
bound proteins must first be sorted at the TGN into membrane bound-vesicles, where they are then
incorporated into the surface membrane. The proper/specific heterodimerization of UPKs, is a
prerequisite for exit from the ER 92. Along the ER are export sites, which are specialized domains
where COPII-dependent export from the ER occurs

97-99

. COPII (a vesicle coat protein) induces

budding from the ER membrane, creating a coated vesicles that undergoes direct trafficking to the
Golgi

100-104

. Once in the Golgi, these immature vesicles begin to maturate/differentiate via

enzymes that catalyze the addition and removal of glycosylations

105,106

. Secretory proteins are

then packaged into vesicles destined for the membrane surface in the TGN.
While not well understood, DFV are thought to initiate in one of two ways: the first, in the
TGN where they are then transported to the apical surface of the superficial cell; the second, from
the endocytic recycling pathways that allow for the regeneration of DFV following voiding
90,107,108

. Rabs are family of small GTPase proteins and are key regulators of vesicle transport 109-

112

. Khandelwal et al (2008) found that Rab11a was essential for the exocytosis of DFV and the

regulation of stretch-induced exocytosis of UPK-filled DFVs in bladder superficial cells

113

.

Similarly, Rab27b was found to also be associated with DFV trafficking in bladder superficial
cells; however, this association was specific only to apical facing DFVs and not the plasma
membrane

114

. Taken together, the association of Rab11a and Rab27b to uroplakin-filled DFVs

suggests the Rab proteins playing a role in the sorting of membrane-bound UPK plaques. Other
apical targeting membrane proteins such as myelin-and-lymphocyte protein, also aid in delivery

10

of UPK-filled DFVs to the membrane surface of superficial cells

115

. Trafficking of UPK

throughout the superficial cell, is summarized in Figure 1.3.

Figure 1.3 The trafficking of and recycling of uroplakin proteins (UPK) throughout the superficial cell. UPK undergo a series of
glycosylations within the ER, golgi, and trans golgi network, which allow UPK to transverse the cell. Fully formed UPK plaques
are expressed along the apical surface of the superficial cell, thus allowing the bladder to expand and contract during voiding.
These plaques are eventually endocytosed and recycled.

1.7 Injuries of the Bladder and Regeneration: Urinary Tract Infections
UTIs are primarily caused by uropathogenic E. coli (UPEC). In the United States, the
annual incidences of UTIs in females is greater than 10%, while 60% of women will be diagnosed
with a UTI in their lifetime

116,117

. The cost associated with UTIs in the US, is particularly

burdensome, societal cost has ballooned to approximately US$3.5 billion per a year 118.
The pathogenic cycle of UPEC during an infection has been well studied. UPEC is typically
derived from the gut, and goes onto colonize the urethra, and subsequently migrates into the
bladder. Type 1 pili and pyelonephritis-associated (P) pili are essential for the binding of UPEC
onto the surfaces of the urinary tract

119

. At the tip of type 1 pili are FimH adhesin, which binds

11

UPIa, which allows for the internalization of UPEC into superficial cells

120

. UPEC is able to

subvert the host response by their internalization, going on to multiply within the protected
intracellular niche forming biofilm-like intracellular bacterial communities (IBCs). The formation
of IBCs allows for the replication of UPEC, evading host mediated expulsion of bacteria. In
response to the infection, the host activates a number of pathways to offset tissue damage and
offset UPEC invasion. We see the secretion of pro-inflammatory cytokines such as interleukin-6,
the recruitment of monocytes and neutrophils, and the induction of programmed cell death, which
results in the sloughing off of IBC-ridden superficial cells. The exfoliation of superficial cells into
the urine aids in the overall reduction of bacterial burden of bladder. However, the importance of
superficial cell barrier function is evident here, loss of the superficial cell layer exposes the
intermediate cell layer to UPEC. Exposure of the transitional cell layers results in the formation of
quiescent intracellular reservoirs (QIRs), which are late endosomal/early lysosomal (Lamp1)positive vesicles in which UPEC is able to lay dormant in the urothelium until a second infection,
or an injury to the urothelium, causes the bacteria to be exposed and cause reinfection

121

. The

pathogenic cycle of UPEC is illustrated in Figure 1.4.
Following the exfoliation of superficial cells, the intermediate and basal cells rapidly
activate regenerative cues to restore the urothelium. Within 3-6 hours of UPEC infection, genes
associated with apoptosis, differentiation, proliferation, cell-to-cell contact, and stress response,
are activated 122. Bone morphogenetic protein 4 (Bmp4) was identified as a regulator of urothelial
proliferation and differentiation after UPEC infection

122

. Bmp receptor type 1a (Bmpr1a) was

found to be expressed within the basal cell compartment of the urothelium, while its ligand, Bmp4
is localized to the mesenchymal compartment 65. Mysorekar et al (2009) showed that ablation of
Bmpr1a resulted in reduced proliferation of the basal cell compartment 12 and 72 hours post
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infection. Furthermore, Bmpr1a null bladders also showed reduced expression of Bmp4 signaling
pathway, through TGIF, p63, and p27kip1 65. As a member of cyclin dependent kinase inhibitors,
p27kip1 inhibits cell cycle progression at G1. Thus, p27kip1 is also used as a marker of terminally
differentiated superficial cells.

Figure 1.4 The pathogenic cycle of uropathogenic E. coli (UPEC). Within the first 24 hours post infection (hpi), UPEC invades
and attaches to superficial cells, forming intracellular bacterial communities (IBCs). Superficial cell death and exfoliation is
triggered, and there is an influx of neutrophils (which transverse the epithelium), and macrophages. There is also activation of the
stem cell niche and regenerative signals. Following the clearance of bacteria, there remains quiescent intracellular reservoirs
(QIRs) 14 days post infection, which can give rise to subsequent re-infections.

1.8 Autophagic Regulation of the Urothelium Under Homeostasis and in Response to Stress
Autophagy is an evolutionarily conserved and highly regulated cellular program for the
degradation and recycling of cellular components. The targeting and trafficking of organelles to
the lysosome for degradation, is a fundamental process for the homeostatic maintenance of cells,
and response to injury/stress. There are three primary forms of autophagy: microautophagy,
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macroautophagy, and chaperone-mediated autophagy (macroautophagy will be referred to as
autophagy for the purpose of this document) 123.
Autophagy occurs in a step-by-step process. The first is the initiation of autophagosome
formation: kinase ULK1 activity is necessary for the recruitment of Beclin-1, ATG14L1 and others
to form a complex which localizes to the site of the phagophore. The conversion of LC3I to LC3II
initiates the elongation of the autophagosome. ATG7, ATG5, ATG16L, and ATG12 recruit
additional membranes which allow for the expansion of the autophagosome. Closure and
trafficking of the autophagosome is mediated by EPG5 and Rab GTPase proteins. Lastly, the
autophagosome fuses with the acidic lysosome, which results in the degradation of the vesiclefilled contents. 123,124 This process and it’s components are summarized in Figure 1.5.

Figure 1.5 The autophagy pathway

Following the degradation of cellular material, the now broken-down byproducts can be
recycled for the production of new cellular components, and can be used to generate energy during
stress conditions such as nutrient starvation 125. Over the last 15 years, our understanding of cellular
inducers of autophagy have greatly expanded our understanding of the role of autophagy during
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stress conditions and homeostasis. Many stress response pathways have been shown to be coupled
with autophagy, such as the integrated stress response and the ER stress response

126,127

. These

processes are both extremely important in the overall maintenance of the cell.
The autophagic pathways has additionally been shown to play a role in the host mediated
anti-pathogenic response. Autophagy genes and proteins have been shown to play a myriad of
roles in innate and adaptive immunity 128-130. In the bladder specifically, mice hypomorphic for the
autophagy gene ATG16L1, which plays a role in autophagosome maturation, have increased
clearance of UPEC upon infection, and reduced latent reservoir formation

131

. This was due to

increased secretion of interleukin-1β (IL-1β) by macrophages 131,132.
In humans, 50% of Caucasians carry a T300A variant of the gene ATG16L1, which is
associated with increased risk of developing a form of inflammatory bowel disease, Crohn disease
133,134

. As described in Chapter 5, mice carrying the T300A variant have diminished QIRs

formation, which was recapitulated by mice lacking genes elongation factors ATG7 and
ATG16L1, in the urothelium. The interaction of RAB33B with ATG16L1 and other secretory
RABs, were important for the exocytosis of UPEC from the urothelium. Furthermore, mice
containing the T300A variant displayed gross urothelial architectural defects such as increased
vesicle congestion and aberrant accumulation of UPK. Taken together, these results suggest the
T300A variant of ATG16L1 alters vesical trafficking within the urothelium, which in turn disrupts
intracellular UPEC persistence.

1.9 The Unfolded Protein Response (UPR)
Cellular maintenance and health is contingent upon proper protein synthesis and regulation,
in a process called protein homeostasis (proteostasis). Disruption to proper proteostasis, activates
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an evolutionarily conserved response called the Integrated Stress Response 135,136. Protein folding
is an error prone process, unlike the tightly regulated processes of DNA replication, transcription,
and translation 137. The accumulation of misfolded proteins within the ER, triggers a process called
the unfolded protein response (UPR). UPR is a multistep process in which can activate either cell
survival (restoration of protein homeostasis) or programmed cell death (when protein
accumulation in the ER burden is too much). Activation of UPR impacts most aspects of secretory
pathways: modification of the rate of protein synthesis, protein folding, trafficking to and from the
ER, protein quality control, and the elimination of misfolded protein

138

. Mammalian UPR is

initialed by three main protein sensors that activate signaling pathways: PERK, IRE1𝛼, and ATF6
(Figure 1.6).

Figure 1.6 Summary of the unfolded protein response. The accumulation of misfolded protein in the ER triggers UPR. There are
three signaling pathways under UPR that control cellular response to stress, this occurs via ATF6, IRE1a, and PERK.
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Binding Immunoglobulin Protein (BiP, also known as GRP78 and HSPA5) is a molecular
chaperone located in the lumen of the ER, where it binds newly synthesized protein, aids in its
folding and translocation 139-141. In this unstressed state, BiP is bound to PERK, IRE1𝛼, and ATF6
which are in an inactive state. The buildup of misfolded protein leads to the accumulation of BiP
and its disassociation from the three ER transmembrane signal transducers. Activated PERK
oligomerizes and phosphorylates eukaryotic translation initiation factor 2 subunit-𝛼 (eIF2𝛼),
which reduces global translation and protein folding 142,143. Phosphorylated eIF2𝛼 also initiate the
translation of genes stress-related genes such as activating transcription factor 4 (ATF4) 136,144,145.
ATF4 enhances the expression of genes involved in amino acid metabolism, protein synthesis,
apoptosis 136,146,147. It is here that ATF4 acts as a master regulator of UPR mediated survival and
death. Inducing the transcription of another factor C/EBP homologous protein (CHOP;
GADD153/DDIT3), together with ATF4, can regulate PERK-mediated transcription and
translation

148-151

. CHOP and ATF4 can form a feedback loop to dephosphorylate eIF2𝛼 and

restore protein synthesis, by inducing expression of GADD34

152-155

. Similarly, increased

expression of ATF4 and CHOP upregulates protein synthesis, thus leading to proteotoxicity and
cell death

149,156

. Downstream targets of CHOP are shown to cause ER-stress induced apoptosis

157

.
IRE1𝛼 is a type-1 ER transmembrane protein that contains two functional domains: an

endonuclease

and

a

kinase.

Activation

of

IRE1𝛼

induces

oligomerization

and

autophosphorylations 158,159. IRE1𝛼 excises 26 base sequence from the transcription factor X-boxbinding protein 1 (XBP1), creating an open reading pair 160-162. XBP1 transcription factors lead to
the upregulation of ER chaperone genes that aid in protein folding, secretion, and translocation
138,143,163

. Another signal cascade activated by XBP1 is ER-associated protein degradation (ERAD)
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pathways, which targets misfolded proteins for ubiquitination and degradation

164,165

. While the

biological implications are still under investigation, IRE1-dependent decay (RIDD) is a process
by which IRE1𝛼 can cleave microRNAs, inducing their degradation

166-169

. The degradation of

microRNAs is speculated to decrease overall mRNA levels, thereby reducing the protein folding
load in the ER

138

. ER-stress induced apoptosis can also be activated by the IRE1𝛼 pathway.

microRNAs that negatively control caspase 2, may be degraded by RIDD, thus inducing apoptosis
169-171

.
ER-stress induced dissociation of ATF6 from BiP, results in the translocation of ATF6

from the ER to the Golgi, where it is cleaved by site-1 protease (S1P) and S2P 172. This fragmented
ATF6p50 transcription factor targets ER stress-response elements 173,174. Furthermore, ATF6 can
act in concert with XBP1 to promote transcriptional regulation of ER chaperones and enzymes that
promote the folding, maturation, and degradation of misfolded proteins 175-177.
In conclusion, at the crux of UPR is the decision making complex of whether to promote cell
survival or activate cell death. Through these three interconnected pathways, ER proteostasis is
maintained via a number of feedback loops that enable the cell to survive, given that ER stress
does not persist long-term.

1.10 The Role of IFRD1 in Proliferation, Regeneration, and Stress Reponses
My initial interest for my thesis work was to identify a novel regulator of urothelial
plasticity. Three aspects of the urothelium have been of particular interest to me, are: the
maintenance of long-term quiescence, rapid induction of regeneration upon injury, and the
stressful/toxic nature of its environment due to urine. I therefore sought to identify a gene that
would play a role in these three areas. My criteria for this novel gene would have to satisfy the
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following conditions: 1) Under homeostatic conditions in the young healthy bladder, this gene
must be readily expressed. 2) Upon injury, this gene is rapidly activated, coinciding with the early
stages of regeneration. 3) Expression and function of this gene will be decrease with age. I first
became aware of the gene IFRD1, from our colleagues in the lab of Dr. Jason Mills. Willet et al
(2018) provided evidence of the emerging role of autophagy in regeneration of tissue following
metaplasia-inducing injury. Paligenosis has been described as a conserved fundamental process by
which differentiated cells of the stomach and pancreas re-enter the cell cycle in a three phase
process 178. Upon injury, the mature cell first induces the autodegradation of its cellular material.
The cell then induces metaplastic gene expression, and following passing the mTOR checkpoint,
re-enters the cell cycle during the last phase 178. Inhibition of autophagy or autophagic components,
results in cellular arrest and cell death 178,179. Miao et al (2020) went on to identify IFRD1 as being
required for phase 3 of paligenosis, re-entry into the cell cycle. The process of paligenosis, and
particularly phase three, became of interest to me because of the differentiated and quiescent nature
of the urothelium. In order to respond to any stimuli, the cells of the urothelium must re-enter into
the cell cycle. Based on this knowledge, I next examined whether IFRD1 fit the criteria for my
gene of interest.
Our lab had previously performed an unbiased RNA-sequencing analysis of young (6-10
weeks old) and aged (18-months old) bladders, before and after UPEC infection. Using this data,
I found that IFRD1 indeed satisfied all three criteria outlined previously. IFRD1 was expressed at
baseline in the young uninfected bladder, and this expression decreased with age. Upon UPEC
infection, IFRD1 was rapidly activated within 6 hours post infections. Further support from
literature indicates the role of IFRD1 in both regeneration and stress response. For these reasons,
investigating the role of IFRD1 in urothelial plasticity, became the focus of my thesis work.
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Interferon-related developmental regulator 1 (IFRD1) was first identified as a gene
expressed in astrocytes followed by mitogen stimulation

180

. Vietor et al (2002) reported

interactions between IFRD1 and SIN3 histone deacetylase (HDAC) complexes 181. SIN3 is thought
to serve as the master regulator of scaffold, and as a corepressor of transcription via HDACs 182.
Together, these interactions are involved in a number of biological and cellular processes. The
major catalytic subunits of SIN3/HDAC complex, are RPD3 and HDAC1/2 in yeast and mammals
respectively. Inhibition of RPD3 in drosophila cells induces apoptosis

183

. In SIN3B-/- mouse

embryonic fibroblast, cells displayed impaired G0 arrest, indicating a role of SIN3B in control of
cell cycle progression 184. This is of particular interest in the urothelium, superficial cells are in a
state of terminal differentiation and quiescence.
IFRD1 has been implicated as a gene upregulated during regeneration of several tissue
types

185

. In vivo stimulation of skeletal muscle cell regeneration resulted in the upregulation of

IFRD1, which acts as a coactivator of MyoD and a negative regulator of NF-𝜅B

186

. In

differentiating myoblast lacking IFRD1, increased cyclin D1 expression was observed. This
further supports the role of IFRD1 in progressive exit from the cell cycle. Bone remodeling and
homeostasis, are tightly regulates processes 187. IFRD1 was shown to be a critical mediator of cellautonomous

regulation

of

osteoblastogenesis

and

osteoblast-dependent

regulation

of

osteoclastogenesis 188. IFRD1 also attenuates the deacetylation of 𝛽-catenin by HDAC, therefore
resulting in its nuclear accumulation of 𝛽-catenin. This results in subsequent promotion in bone
resorption

189

. IFRD1 has also been indicated to promote crypt cell proliferation and enterocyte

differentiation following small intestine resection 190. Interestingly, to date the loss of IFRD1 under
homeostatic conditions has only been reported to have a baseline phenotype in the development of
neurodegenerative disease spinocerebellar ataxias
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191

. Unlike other organs which require some

form of an injury to induce a phenotype in the absence of IFRD1, neuronal cells like bladder cells,
are long-lived. Taken together, IFRD1 can promote both regeneration and differentiation following
injury.
UPR activating chemical tunicamycin, induces the stabilization of IFRD1 mRNA through
the phosphorylation eIF2a, resulting in increased expression of IFRD1 mRNA and protein

192

.

Furthermore, Zhao et al (2010) identified IFRD1 as regulated by cellular stress response 192. ATF4
has also been predicted as an upstream regulator of IFRD1.

1.11 Conclusions and Key Questions
The bladder urothelium is a remarkable tissue, in that it undergoes multiple dynamic
changes throughout the day, and it maintains long-term quiescence. As the primary location for
one of the most common infections in humans (UTIs) and the fourth most common cancer in men
(bladder cancer), much of what is understood of the bladder comes from the injured/diseased state.
The term “quiescence” is typically thought of as an inactive state, indicating exit from the cell
cycle. One of the hallmarks of the urothelial is it’s impermeable barrier function. How the
urothelium governs long term quiescence while actively maintaining the barrier, is not well
understood. Previous work has shown rapid activation of regenerative pathways upon injury.
Under homeostasis, others have shown the integral role of the trafficking and folding of uroplakin
proteins. Here, we propose that under homeostasis, the bladder urothelium is quite active. The
ability to offset potential pathogen and toxin from urine, coupled with the constitutively active
packaging, trafficking, and recycling of uroplakins; suggest a more active state of homeostasis.
This thesis will show that the ER stress response plays an integral role the maintenance of the
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homeostatic urothelium. We’ve identified IFRD1 as a gene that plays a unique role in the
urothelium, modulating its ability to respond to stress signals.
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Chapter 2: Reflections on the Void: The Art of
Micturition Analysis

This chapter is an editorial that was published in American Journal of Physiology-Renal
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2.1 Editorial
Many men and women of all ages experience lower urinary tract symptoms (LUTS) such
as overactive bladder, voiding obstructions, and urinary tract infections. In addition to significantly
decreasing quality of life, LUTS are often lifelong problems that add substantially to medical costs.
Given that LUTS often worsen with age and that our aged population is growing, we must identify
new means to treat these afflictions, which will require a more detailed understanding of the
underlying mechanisms.
Mice are a useful model to study LUTS because many of these symptoms, such as urinary
tract infections, can be experimentally induced 1. Additionally, investigators can examine the effect
of variables such as obesity, diet, sex hormones, drugs, and genetics on urinary function. One
method to assess such effects is cystometry, in which a catheter is placed into the bladder of a
mouse and used to measure bladder capacity, peak bladder pressure, and spontaneous contractility
2

.However, this assay requires anesthetization and is difficult, invasive, and time-consuming.
Some researchers have instead begun using an assay long used by those studying mouse

behavior, the void spot assay (VSA). In this assay, the investigator measures the number, size, and
spatial distribution of urine spots on filter paper over a defined period of time. The VSA requires
no specialized equipment and is easy to perform, reproducible, inexpensive, non-invasive, rapid,
and can be repeated on the same mouse several times. Studies have shown that there are many
different factors that can have an effect on voiding behaviors. Spontaneous urination patterns can
be used to evaluate how changes in environment, age, and genetic background impact urinary
function

3,4

. This assay has provided researchers with a non-invasive tool to further study the

effects of stimuli on LUTS. Despite these major advantages, there have remained concerns
regarding this assay can be successfully used to distinguish alterations in urinary physiology.
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To address this important question, the National Institute of Diabetes, Digestive and
Kidney Disorders (NIDDK) tasked a consensus group with evaluating the methodologies,
interpretations, and findings of VSAs. In this issue, Hill et al., 2018 provide a comprehensive
report on the outcome of this group's work, describing numerous research questions that have been
addressed with the VSA, pointing out parameters that should be considered and reported on for
VSAs. We highlight these suggested parameters and optimal approach for conducting a VSA in
(Figure 2.1).
Historically, cystometry, a clinical diagnostic procedure that measures the contractility of
the bladder has been used to evaluate bladder capacity, peak bladder pressure and spontaneous
contractility 2. There have been some divergent findings using the two assays which suggest that
VSA and cystometry may not be necessarily interchangeable. While some groups have been able
to confirm VSA results using cystometry (and vice-versa) 5, others have shown contrasting data
between the two methods 6. Based on these and other findings, the consensus of the group is that
cystometry and VSA both provide information about physiological changes due to LUTS, albeit
providing different types of measurements.
Hill et al., 2018 outline how investigators in the field could use the VSA to gain new
insights into mechanisms underlying disorders that effect the lower urinary tract. The relationship
between the voided volume and the urine spot area have been extensively studied 7. In general, the
data collect from VSA includes: the total number of spots, the total voided volume, the average
volume voided, and the spatial distribution of the spots. Depending on the investigators interest,
the changes in these measurements may be interpreted differently. Spatial distribution of spots
may be particularly interesting due to mice engaging in “wall seeking” behavior. This is thought
to be related to anxiety, fear, and learning, and is an inherited but modifiable property. Because of
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this, mice will often urinate near the walls/outer edges of the cage. Therefore, changes in the ratio
of edge voiding to center voiding are an indicator of aberrant void behavior. Interestingly, these
behaviors occur independent of enclosure shape.
Furthermore, researchers could use the VSA to assess the effects of genetic differences on
susceptibility to urinary tract infections. For example, it has been shown that C3H/HeN mice are
more susceptible to UTIs than C57BL/6J mice 8. Sex, and age are important considerations as
women are disproportionally affected by UTIs, and postmenopausal women are highly susceptible
to recurrent urinary tract infections 9. Studies using VSA to examine voiding behaviors in different
mouse strains at different ages, with and without infection, may provide valuable insights into
urinary tract infection pathogenesis, incidence of reinfections, and efficacy of current and new
therapies.
One major disadvantage of VSA that Hill et al., 2018 address is that small differences in
procedure can lead to variable results. Some of the biggest variations can potentially come from
the use of a grid, the type of filter paper used, and most notably, the data analysis method.
Furthermore, there is no consensus of how each experiment should be planned. In this review, Hill
et al provides a valuable list of VSA "best practices”, which provides insight as to how to conduct
experiments and report results. When similar protocols were used, different laboratories in
different geographical locations produced consistent results, further supporting the reproducibility
of VSA 10. Additionally, by archiving VSA filter images, future work can be done to compare
results between experimental conditions and labs. The review also highlights an open source
software called “Void Whizzard” (http://sites.imagej.net/VezinaLab) that was recently developed
by Vezina and colleagues to facilitate rapid and objective analysis of VSA data. This software
package may ultimately enable VSA to be a standard tool in the analysis of LUTS. Thus, when
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done correctly and consistently, void spot assays could provide a unique tool that can be used to
further understand the physiology of the lower urinary tract.
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2.3 Figure Legend and Figure:
Figure 2.1 Schematic depicting best practices for the design and analysis of void spotting assays.
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Figure 2.1:Schematic depicting best practices for the design and analysis of void spotting assays
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3.1 Abstract
Aging has multifaceted effects on tissue homeostasis and response to infections in the
female genitourinary tract. Bladder diseases characterized by chronic inflammation are highly
prevalent in older women as are recurrent urinary tract infections (UTIs). Recurrent UTIs (rUTIs)
lead to chronic inflammation of the bladder mucosa and cause lower urinary tract symptoms that
persist even after the infection is cleared. Vaginal estrogen therapy (VET) has long been used for
the treatment of rUTIs, however its mechanism of action remains unclear.
Here, we utilized a model of induced menopause in ovariectomized aged (18 months old)
mice. Following surgery, mice were subsequently treated with VET. Mice were then infected with
Uropathogenic E. coli (UPEC), which cause UTIs and course of infection investigated.
Inflammatory cytokine response was assessed before and during infection using ELISA. RNA
sequencing analysis was used to compare the inflammatory status of the young versus aged bladder
and principal changes confirmed via qRT-PCR to determine the effects of VET on bladder
inflammation. Finally, impact on age associated tertiary lymphoid tissue (TLT) formation was
evaluated histologically.
Aging was associated with enhanced production of proinflammatory cytokines and influx
of inflammatory cells to the mucosa even prior to infection. Upon induction of UTI, aged bladders
displayed significantly increased formation of UPEC biofilms, quiescent intracellular reservoirs,
and subsequently increased spontaneous recurrent UTIs. The acute inflammatory response to
infection was exacerbated even further in aged bladders. In addition, we observed increased uterine
horn atrophy followed by reproductive quiescence in aged mice. VET not only mitigated uterine
atrophy, but therapy was also associated with reduced rUTIs, reduced number of bacterial
reservoirs in the urothelium, and dampened immune response and promotion of terminal
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differentiation of urothelial cells. Bladder tertiary lymphoid tissue (bTLT) lesions were also
reduced with VET, with associated decrease in signals important for bTLT formation. Finally, we
determined that VET reverses age associated upregulation of inflammatory genes and pathways.
Our data suggest that VET is effective by reducing age-associated hyper-inflammatory
conditions in bladder mucosa and in enhancing the host response to infection.
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3.2 Introduction
As the world population continues to grow, so does the aging population. By 2050, the
world’s population of individuals over the age of 60 years is projected to make up 22% of the
population 1. The aging body undergoes a number of changes which is further compounded in
women due to the reduction of the sex hormone, Estrogen, post menopause. Up to 50% of
postmenopausal women will experience urinary tract infections (UTIs), the second most common
infection in the elderly, accounting for approximately 25% of all infections2. UTIs result in an
estimated 13 million outpatient visits and cost $2 billion per year in the US alone 3. UTIs have an
unusual propensity to recur, and over 50% of UTI cases in women over 55 years of age recur
within one year despite appropriate antibiotic treatment 4,5. Moreover, recurrent UTIs (rUTIs) lead
to chronic inflammation of the bladder mucosa and cause lower urinary tract symptoms that persist
even after the infection is cleared6-8. Thus, there is great need to understand the mechanisms
driving chronic inflammation and to determine therapeutic regimens to treat and prevent UTIs in
the elderly.
Hormone therapy with Estradiol (E2) has long been used to treat a number of urinary
symptoms in post-menopausal women9-17. Estrogen treatment supplementation has been
associated with increased production of antimicrobial peptides in humans and strengthening of
urothelial barrier function 18. Targeted vaginal estrogen therapy (VET) has been shown to decrease
the rate of rUTIs in postmenopausal women and reducing the levels of proinflammatory cytokine,
interleukin-6

10,19-23

. While the effectiveness of vaginal estrogen therapy has been shown, the

mechanism by which it works remain to be elucidated.
Prior studies have used mouse models to address the interplay between aging and immunity
and impact of estrogen therapy on UTIs

18,24,25
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. Our group and others have utilized the

ovariectomized (OVX) young mouse as a model of induced hormone depletion and demonstrated
that OVX mice harbored greater bacterial burden, increased formation of bacterial reservoirs that
can seed rUTIs, and elevated circulating IL-6. E2 supplementation limited the infection and
inflammatory response in part by rapidly promoting urothelial regeneration via BMP4 signaling
25

. Luthje et al. confirmed that ovariectomy results in higher bacterial burdens in the bladder and

urine

26

. Additionally, they reported that urines of postmenopausal women (who have low

estrogen) exhibited higher urothelial exfoliation during UTI than did urines of premenopausal
women. These studies indicate a clear role of estrogen in modulating mucosal defenses in mice
and women. Recent work has begun to uncover how aging itself fundamentally alters the bladder
immune landscape. Ligon et al. demonstrated that unperturbed aged bladders harbor tertiary
lymphoid tissue (bTLT), which serve as centers for B cell recruitment, activation, and
differentiation into plasma cells

27

. bTLT appear as a feature of aging concomitant with

reproductive senescence (~9 months of age) and appear to be unique to female bladders, indicating
that ‘menopause/reproductive senescence’ are key transitions for age associated changes in the
urinary tract. In addition, bTLT formation was shown to be dependent on TNF-𝛼 and CXCL13 27.
Here, we explore whether VET reverses/improves age associated immune and inflammatory
changes.
Here, we utilize two murine models of aging to improve our understanding of the impact
of aging and postmenopausal state on bladder inflammatory status and UPEC infection
pathogenesis and determine the mechanism underlying VET efficacy in ameliorating these
conditions. Using aged mice (18 months old mice; ~65 year old women), we show that aging is
associated with baseline increase in inflammatory status, increased rUTIs, and elevated
proinflammatory response to infection. We find that VET restores the age-associated uterine tissue
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atrophy with the mice re-entering estropause; a significant decrease in rUTI concomitant with
increased terminal differentiation. Further, we found that VET reverses the age-associated
upregulation of inflammatory-related genes and pathways in aged mice and reduces the number
and size of bTLTs via downregulation of TNF-𝛼 and CXCL13. Together, our findings elucidate a
mechanism of action of VET and support use of VET in postmenopausal women with or without
a history of UTIs.
3.3 Results
3.3.1 UPEC infection of aged mice results in increased urinary tract infection recurrences,
hyperinflammatory response, and reservoir formation
To determine the effect of aging on the UPEC pathogenic cycle, we infected young (10weeks old) and aged (18-months old) female mice and monitored the progression of infection over
14 days post infection (dpi). We found no significant differences in infectivity or initial responses
between young and aged mice. However, by 7-14 dpi aged mice had significantly higher rate of
spontaneous bacteriuria, indicative of a recurrence (Figure 3.1A).
Key aspects of the host response to UPEC infection includes the sloughing of urothelial
superficial cells, activation of proinflammatory cytokines such as interleukin-6 (IL-6) and IL-8
28,29

, and the influx of immune cells such as monocytes and neutrophils into the bladder mucosa

30-36

. Exfoliation of superficial cells is in part due to high bacterial load in intracellular bacterial

communities (IBCs) within these cells 37-40. Within the first 6 hours post infection (hpi), we observe
exfoliation of large superficial cells containing IBCs in both young and aged mice, as noted in
previous reports 41-43. However, while superficial cell shedding is reduced by 24hpi in young mice,
we find that aged mice exhibit enhanced and prolonged IBC formation and cell shedding (Figure
3.1B), which is sustained through day 3 post infection (Figure 3.1C)
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. Furthermore, urine

cytological analysis reveals polymorphonuclear neutrophils (PMNs) are present in significantly
higher numbers in aged mice compared to young mice (Figure 3.1D). Similarly, the number of
monocytes recruited to the bladder and shed into the urine of aged mice at 24hpi was significantly
higher than those found in young mice (Figure 3.1E). Together, these findings indicate that the
aged animal has a significantly enhanced immune inflammatory response to infection in addition
to having greater numbers of recurrences.
Inflamm-aging is a process in which aged individuals develop chronic low-grade
inflammation due to an increase in pro-inflammatory cytokines such as IL-6 45. Studies have shown
the importance of IL-6 production in response to UTI, in particular, controlling the host
antimicrobial response and aiding in tissue regeneration 44,46,47. Given the age-associated increase
of IL-6 and its role as a proinflammatory cytokine during UTI, we next examined IL-6 levels in
both urine and serum of young and aged mice. Sera IL-6 levels before infection and 24hpi were
significantly elevated in aged mice compared to young mice (Figure 3.1H). While before infection
we did not observe a difference in urinary IL-6 levels, we see that by 6hpi there is a significant
increase in aged mice. Finally, aged mice harbor significant higher number of quiescent
intracellular reservoirs (QIRs) within Lamp-1 positive vesicles which can seed rUTIs 48,49 (Figure
3.1F-G). Taken together, these data suggest an elevated systemic proinflammatory response to
infection in aged mice and increased QIR formation which suggests a possible explanation for
increased rUTIs seen in aged mice and women 48,50.

3.3.2 VET reverses age-associated changes in reproductive tissues
Unlike humans, estrogen levels in aged mice do not typically display a significant decrease
51-53

, and thus ‘aged’ may not directly be reflective of ‘postmenopausal’ mice. Thus, we sought to
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determine whether ovariectomized aged mice would constitute a bone fide “postmenopausal aged’
mouse model” to better understand the potential mechanism(s) of VET action in the aged mouse
bladder. We generated ovariectomized (OVX) aged mice which we then treated with daily VET
for two weeks. Mice were then infected with UPEC and VET was continued twice a week for the
remainder of the study (Figure 3.2A).
First, we found that serum estradiol levels remained unchanged in aged mice before and
after ovariectomy, however levels significantly increased in aged mice treated with VET (Figure
3.2B). The lack of change in estradiol levels in aged mice following ovariectomy may be due to
an increase in adipocyte tissue mass associated with aged mice, which can significantly contribute
to circulating estrogen levels in postmenopausal women

54,55

. Rodents exhibit age-associated

uterine horn atrophy, which we found to be reversed following VET (Figure 3.2C).
Rodent estrous cycling occurs every 4-5 days, consisting of four stages: estrus, metestrus,
and diestrus. It has been shown that around 9-12 months of age, rodents begin to experience
irregular estrus cycles called estropause, and eventual stop cycling all together (termed anestrous
state)

51-53

. We observed that both aged and OVX-Aged mice undergo anestrous, while VET

treated OVX-Aged mice re-enter estropause (Figure 3.2D). These findings indicated the removal
of ovaries in aged mice do not exacerbate aged-associated changes in estrogen levels and
reproductive tissue. Hereafter, we continued subsequent analyses with ‘aged’ to represent
ovariectomized aged animals and ‘aged+VET’ to represent ovariectomized aged mouse cohorts
given VET.

3.3.3 VET reduces rUTIs and promotes terminal differentiation of the aged urothelium
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We previously assessed the role of systemic E2 instillation on UPEC pathogenesis in a
young OVX mouse model 25. Here, we determined the impact of VET in aged mice. While there
was no impact of VET in the initial states of infection in aged mice similar to what was previously
observed in young mice

25

, we found VET treatment was associated with significantly fewer

instances of spontaneous bacteriuria indicative of rUTIs (Figure 3.3A). Additionally, we did not
see a difference in serum or urine IL-6 levels before or during infection between aged and aged
+VET mice (data not shown). Given the significant decrease in rUTIs in the aged +VET group,
we next sought to determine whether there was a decrease in QIRs. Histological analysis revealed
fewer QIRs in the VET treated mice (Figure 3.3B).
Superficial urothelial cell exfoliation due to infection has to be restored via terminal
differentiation of underlying cells into new superficial cells with the activation of regenerative
pathways to restore the urothelium, including BMP4 pathway leading to increased expression of
p27kip1 indicating exit from the cell cycle and terminal differentiation 56-60. We determined that
VET treated aged mice contained significantly greater number of p27kip1 positive nuclei than
aged mice suggesting that VET might promote terminal differentiation (Figure 3.3C). These
results suggest VET decreases the incidence of rUTI by reducing QIR formation and promoting
terminal differentiation of superficial cells to restore urothelial barriers.

3.3.4 VET reverses age-associated upregulation of inflammatory genes
To better understand the role of aging in the increased susceptibility to UPEC infection,
we performed a RNA-sequencing analysis of bladders from young and aged mice. Pathway
analysis of our uninfected controls revealed the upregulation of a number of inflammation-related
genes in the transcriptome of aged mice compared to young mice (Figure 3.4A). In particular, we

51

noted consistent increase in markers of inflammatory cell death, recruitment of macrophages, and
response to tissue damage. Our data shows that at baseline, uninfected aged bladders express
higher levels of IL-18 and receptor IL-18r1, which is necessary for IL-18 signaling, along with
proinflammatory cytokine IL-1β (Figure 3.4A). These pathways are indicative of capase-1
dependent inflammatory response61, wherein pro-forms of IL-1β and IL-18 are cleaved into mature
proinflammatory cytokines, and released upon cell lysis, thereby promoting a robust inflammatory
host response

62-64

. Tissue resident macrophages play an instrumental role in the homeostatic

maintenance, sensing and responding to tissue damage. As an important effector cell of the innate
immune system, macrophages use a number of receptors to sense and respond to danger signals
efficiently

65-67

. CD163L1 is a group B scavenger receptor family, and is highly expressed on

macrophages where it colocalizes with CD163 68. Similarly, CD68, which is expressed primarily
by mononuclear phagocytes and tissue macrophages, is a scavenger receptor

69-71

. Macrophage

inducible Ca2+-dependent lectin receptor (Mincle), which is encoded by the gene CLEC4E, is
expressed by myeloid cells including monocytes and dendritic cells, and functions as a tissue
sensor

72-74

. We observe increased expression of CD163L1, CD68, and Clec4e in the aged

uninfected bladders (Figure 3.4A). Tnfaip8l2 functions as a myeloid cell derived immune
checkpoint regulator 75. Increased expression of Tnfaip8l2 is associated with autoimmune diseases
76,77

. Our data revealed that Tnfaip8l2 expression was increased in aged bladders (Figure 3.4A).

Thus, together, our findings in naïve bladders indicate that age is associated with a higher proinflammatory phenotype.
Next, we sought to determine whether VET has an impact on these signals and pathways.
We found that VET in aged mice resulted a significant decrease in IL-18r1 (Figure 3.4B) and IL1β (Figure 3.4C). We further showed that VET significantly reduces expression of CD163L1
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(Figure 3.4D), CD68 (Figure 3.4E), CLEC4e (Figure 3.4F) and TNFAIP8L2 (Figure 3.4G). In
contrast, we note an increase in expression of anti-inflammatory marker, IL-4 (Figure 3.4H).
Tissue repair requires macrophage polarization into pro-regenerative phenotype which occurs via
the secretion of anti-inflammatory cytokine IL-4 by T lymphocytes which reduces production of
pro-inflammatory cytokines78-80. We note that compared with young naïve bladders, aged bladders
express decreased expression of IL-4. This is consistent with increase in terminal differentiation
makers due to VET. Together, we speculate that VET is effective as a therapy due to dampening
of pro-inflammatory pathways in aged bladders while promoting a tissue regenerative phenotype.

3.3.5 VET induces the regression of bladder tertiary lymphoid tissues in aged mice
We have recently shown that aged bladders are characterized by presence of tertiary
lymphoid structures (bTLT) which begin to form around 9 months of age in the aged female mouse
27

. bTLT comprise of T and B cells with bona fide germinal centers and have increased expression

of lymphoid chemokine, CXCL13 81, and TNF-𝛼

27

. We found that VET treated aged mice had

fewer bTLT than aged mice alone (Figure 3.5A-B) although this number was not significant.
However, the size/volume of bTLT was reduced significantly in mice treated with VET (Figure
3.5C). The formation of bTLT in the aging bladder is dependent on the inflammatory cytokine
TNF-𝛼, and the expression of chemokines such as CXCL13 27. We found that VET treated aged
mice express significantly reduced tissue TNF-𝛼 compared to aged bladders (Figure 3.5D). While
tissue CCXL13 remained unchanged (Figure 3.5E), serum CCXL13 was significantly reduced in
VET treated animals (Figure 3.5F). These data suggest VET reduces the size of bTLT possibly
via downregulation of TNF-𝛼 and CXCL13, which are both necessary for their formation and
propagation in the aged bladder.
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3.4 Discussion
The menopausal transition in a woman is commonly associated with symptoms and
changes in the urogenital tract including vaginal atrophy, urinary urgency, frequency, and
increased susceptibility to urinary tract infections. Vaginal estrogen therapy has been shown to
have utility in the management of urologic health

82,83

. The mechanisms driving the use of VET

remain to be fully elucidated. In the current study, we employed a mouse model of ovariectomized
aged mice to examine the impact of VET on age associated-inflammatory status of the bladder
prior to and following a UTI. We found that VET was sufficient to reduce baseline inflammation
in the aged bladder as well as limit the inflammatory response after infection. Further, we show
that VET reduced the prevalence of bacterial reservoirs and subsequent incidence of rUTIs in
addition to upregulating the expression of urothelial regenerative markers. Finally, we demonstrate
that VET significantly reduced the size of tertiary lymphoid tissue lesions associated with the aging
bladder. These lesions have been associated with increased incidence of rUTIs. Our findings
provide a foundation for exploring mechanisms of VET action and further underscore the
importance of considering VET for women as they undergo menopause.
Normal estrogen levels has long been associated with having anti-inflammatory functions such
as the downregulation of proinflammatory cytokines, accelerating the resolution of inflammation
in macrophages, and the regulation of cells of the innate and adaptive immune system

84-86

.

Estrogen is a key modulator of the inflammasome response, loss of estrogen coincides with the
increased susceptibility to a number of autoimmune diseases such as rheumatoid arthritis and the
worsening of multiple sclerosis symptoms
enhanced immune response

87-89

. Similarly, estrogen deficiency can lead to an

85,90

. Our data is consistent with the anti-inflammatory properties of

estradiol through the downregulation of proinflammatory cytokines and markers.
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The antimicrobial properties of estradiol in the bladder promotes regeneration and barrier
function of the urothelial following UPEC infection, and our data supports the use of VET to
reduce rUTIs in the aged ‘postmenopausal’ state 18,19,25. VET is associated with reduced expression
of genes involved in pyroptosis and inflammasome activation, myeloid cell markers such
associated tissue macrophages, TNF-𝛼 secreting macrophages, scavenger-receptor expressing
cells, including myeloid cell-derived immune checkpoint regulator, and a marker of
proinflammatory M1 macrophages. We also see the decreased expression of proinflammatory
cytokine IL-1B and an increase in the expression of anti-inflammatory cytokines IL-4 and IL-10.
Reducing the proinflammatory state of the aged bladder before UPEC infection may be key in
reducing the overall enhanced inflammatory response and subsequent damage to the urothelium.
Excessive inflammation may result increased damage to the urothelium and delay in urothelial
regeneration. VET might be particularly useful in dampening inflammation and promoting
terminal differentiation of urothelial cells following UPEC infection.
Recent work has uncovered the age-dependent development of tertiary lymphoid tissue
(TLT) in mouse bladders commencing upon reproductive senescence 27. Aging was also associated
with substantial changes to the naive bladder immune system revealing novel subsets of
macrophages and dendritic cells as well as an enrichment of B and T cells

27

. These tertiary

lymphoid structures are organized with bone fide germinal centers with distinct B and T cells zones
and are dependent on TNF-α and CXCL13 for their formation/maintenance. Somewhat
unexpectedly, we determined that VET appears to induce regression of TLT. Our data suggest
VET may reduce the size and volume of TLT in part by dampening the expression of TNF-α and
CXCL13. The presence of these structures in aged mice and their subsequent regression following
VET needs to be further addressed. Whether and how estrogen signaling may directly or indirectly
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block the formation of bladder TLTs has to be investigated further. If true in postmenopausal
women, this understanding has the potential for being transformative in terms of therapy to limit
rUTIs and dampen inflammatory milieu in the aged mucosa.
During infection, a subset of UPEC subvert host mediated immune defenses to form QIRs
that can persist indefinitely and lead to subsequent cases of reinfection

48

. Conventional UTI

treatments such as antibiotics, are ineffective in the elimination of QIRs 91. We show that VET
reduces the number of QIRs in aged mice following UPEC infection. Understanding the role of
E2 in the formation of these reservoirs has the potential to unveil potential therapeutic targets for
the treatment of rUTIs. Our work provides further support for a beneficial role of VET in
restoration of genitourinary tract homeostasis, reduction of rUTIs, and promotion of antiinflammatory response.
The Women’s Health Initiative sought to identify the risk and benefits of hormone
(estrogen and progestin) replacement therapy in postmenopausal women. The main risk factors
reported by the study were that hormone replacement therapy was associated with increased risk
of coronary heart disease and invasive breast cancer

92

. This led to widespread fear of the

prescription of hormone replacement therapy in postmenopausal women. However, recent studies
are changing the conversation to improve older women’s GU health

88,89,93,94

. Our work adds to

and provides new evidence in support of VET as a therapy in the treatment of rUTIs in postmenopausal women.
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3.5 Experimental Procedures

Mice
All aged mice were 18-months old, and were obtained from the National Institute on Aging. Young
mice 6-10 weeks old, were obtained from The Jackson Laboratory. Mice were held in a pathogenfree and temperature controlled facility, with a 12-hour light/dark photocycle. All animal protocols
were approved and in accordance with Washington University School of Medicine IACUC
standards.

Ovariectomies
Ovaries of female 18-month old C57BL/6 female mice were removed as previously described 25.
In short, two small dorsal skin incisions were made around the ovarian fat pad. The ovaries and
the attached uterine horns were located and pulled through the incision. The ovaries were then
removed using a single cut, applying pressure to the uterine horn to stave off bleeding. Pre-op care
includes the administration Buprenorphine Sustained Release (0.5-1.0mg/kg). All mice were
allowed at least two weeks to recover.

Estradiol Supplementation
Vaginal estradiol cream (ESTRACE cream 0.01%) was applied to mice immediately following
ovariectomy. Each mouse received 0.1mg/kg of estradiol directly into the vagina, daily for two
weeks. Graduated pipette tips were cut above the first notch to create a larger opening. The tip was
then filled with the cream until it reached the following notch. After two weeks, the mice received
the same dose of estradiol twice a week, throughout the duration of the infection.
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Infection
UT189 48 from a frozen glycerol stock was grown statically at 37 ℃ for 24hr in 20 mL of LuriaBertani (LB) broth. The overnight culture was then subculture into fresh 20 mL of LB broth and
grown for 16-18 hrs. Mice were anesthetized and transurethrally catheterized with 50 uL of 107
CFU (colony forming units) bacterial suspension diluted in PBS. Mice were sacrificed day 1
through day 14 post infection, in accordance with the experimental design.

Urine Analysis
Throughout infection, urine samples were obtained from each mouse. Urine samples were then
serially diluted in sterile PBS, 5uL of each dilution was then seeded on LB plates for a total of six
replicates. Plates were counted and calculated as CFU/mL. Urine cytology was obtained by
spinning down 10uL of urine and 40uL sterile PBS, onto microscope slides. These slides were then
fixed, using an open flame, and stained using the Papanicolaou protocol.

Tissue Histology
Following sacrifice, bladders were removed and immediately fixed in methacarn (60% methanol,
30% chloroform, 10% acetic acid). Fixed bladders were then embedded in paraffin and 5
micrometers thick section were stained with hematoxylin and eosin.

Immunofluorescence Analysis
Bladder tissues were sectioned as described above and then stained using the following antibodies:
mouse monoclonal antibody to Uroplakin III (Fitzgerald 10R-U103A), chicken polyclonal
antibody to cytokeratin-14 (1:200, Biolegend 906004), mouse monoclonal antibody to E-cadherin
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(1:250, BD Biosciences 610181), rabbit polyclonal antibody to Escherichia coli (1:250, US
Biological e3500-26), rabbit monoclonal antibody to p27KIP1 (1:250, ABCAM 190851), and
rabbit monoclonal antibody to cytokeratin 5 (1:250, ABCAM 53121). Following three 5 min
washes with PBS, secondary antibodies to Alexa 488, Alexa 594, and Alexa 647 (1:500,
Invitrogen) were applied. Superficial cell nuclei positive for p27kip1 were quantified and analyzed
14 days post infection.

QIR Quantification
Four separate 5 micrometers serial sections over a thickness of 200 micrometers per bladder, were
stained for E. coli (to visualize bacteria) and E-Cadherin (to visualize the outline of epithelial
cells). The total number of QIRs was quantified and reported as #QIRs per bladder.

Bladder Tertiary Lymphoid Tissue Quantification
Hematoxylin and eosin stained sections were imaged using Hamamatsu NanoZoomer 2.0-HT
System. The number of bTLT per bladder were quantified, and the total area of bTLT was analyzed
using NDP.veiw2 software as described Ligon et al (2020).

RNA Sequencing
Preparation of bladders for RNA isolation, sequencing, and data analysis were previously
described

27

. In short, bladders were snap frozen and homogenized for RNA isolation using

RNeasy Mini Kit (Qiagen, 74101). Preparation of libraries was done with Ribo-Zero rRNA
depletion kit (Illumina) and then sequenced on HiSeq3000 (Illumina). Reads were then aligned to
the Ensemble top-level assembly with STAR version 2.0.4b. Gene counts were produced from the
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uniquely aligned unambiguous reads by Subread:feature Count version 1.4.5, and transcript counts
were derived by Sailfish version 0.6.3. Using RSeQC version 2.3, sequencing performance was
determined for the total number of aligned reads, total number of uniquely aligned reads, genes
and transcripts detected, ribosomal fraction, known junction saturation and read distribution over
known gene models. All gene counts were then imported into R/Bioconductor package EdgeR and
TMM normalization size factors were calculated to adjust samples for differences in library size.
Some features, such as ribosomal and any feature not expressed in at least three samples, were
were excluded from further analysis and TMM size factors were recalculated to create effective
TMM size factors. These factors and matrix counts were then imported into R/Bioconductor
package Limma, and the voomWithQualityWeights function was used to calculate the observed
mean-variance relationship of every gene/transcript and sample. Generalized linear models were
then used to test for gene/transcript level differential expression, which were filtered for False
Discovery Rate (FDR)-adjusted p-values less than or equal to 0.05. Adapted from Ligon et al
(2020) and Wang et al (unpublished 2021).

Real-time Quantitative PCR (RT-qPCR)
RNA was isolated from flash-frozen bladders from non-infected mice, using TRIzol (Invitrogen
15596018). Samples were then treated with DNase I (Invitrogen 18068015) to remove any
contaminating DNA. cDNA was synthesized using

SuperScript™ II Reverse Transcriptase

(Invitrogen 18064014). Expression of genes of interest were detected via RT-qPCR using
SsoAdvanced Universal SYBR Green Supermix (Bio-Rad 1725275) on a CFX96 Touch RealTime PCR Detection System (Bio-Rad). List of primers used can be found in the table below.
Relative expressions were calculated using the Double Delta Ct Value, and normalized to 18S.
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ELISA
Serum and urine samples collected from mice were analyzed according to the manufacture’s
protocol. The following kits were used: Mouse IL-6 (R&D Systems DY406) and Mouse
CXCL13/BLC/BCA-1 (R&D Systems DY470).

Statistical Analysis
For time-course experiments, two-way ANOVAs with matching were used with Bonferroni posttests for individual time points. To determine significance between two samples, unpaired t-tests,
paired t-tests, or non-parametric Mann-Whitney U tests were performed by using Graph Prism
software. P < 0.05 was used as the cut off for statistical significance. To determine significance
between treatment groups using RT-qPCR, unpaired t-test was performed using Graph Prism
software.
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Table 3.1 Primer sequences used in qPCR analysis
Gene Name Forward Primer (5’-3’)

Reverse Primer (5’-3’)

IL-18r1

TCACCGATCACAAATTCATGTGG TGGTGGCTGTTTCATTCCTGT

Cd163l1

TGGCCTCTGAGTTTAGGGTCT

CCCTTGGTGTCGAACCAGC

Cd68

TGTCTGATCTTGCTAGGACCG

GAGAGTAACGGCCTTTTTGTGA

Clec4e

AGTGCTCTCCTGGACGATAG

CCTGATGCCTCACTGTAGCAG

Tnfaip8l2

TCAGCTCAAAGAGTCTGGCAC

CTGGTCTCGTCGATAAAGAGATG

IL-4

GTCTGCATCAAGACGCCATG

CGTTGCTGTGAGGACGTTTG

IL-1β

GCAACTGTTCCTGAACTCAACT

ATCTTTTGGGGTCCGTCAACT
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3.7 Figure Legends and Figures

Figure 3.1 UPEC infection of aged mice results in increased urinary tract infection
recurrence, hyperinflammatory response, and reservoir formation
(A) Percentage of mice with positive UPEC urine titers >103 CFU/mL at given time points (young
8-weeks old n=13-38, aged18-months-old n=19-41). (B) PAP staining of urine samples from
young and aged mice at 24hpi, with red arrowheads indicating IBCs, black arrow heads depict
superficial cells, and yellow asterisk indicating neutrophils. (C) Percentage of mice with IBC in
urine from young (n=18) and aged (n=18) mice following UPEC infection. (D,E) Urine
inflammation score indicating aged mice exhibit more neutrophil (D) and monocyte (E) infiltration
than young mice 24 hours post UPEC infection. (F) Immunostaining of QIRS in bladders of aged
mice (green: UPEC, red: E-CAD, and blue: DAPI). (G) Quantification of QIRs in young (n=15)
versus aged (n=20) mouse bladders at 14 days post infection. (H) Levels of serum IL-6 in young
(n=4) and aged (n=6) mice, uninfected and 24 hours post infections. (I) Urine IL-6 levels of young
(n=3) and aged (n=6) mice 24 hours post infection. *P<0.05 and **P<0.001 by unpaired two-tailed
T-test.

Figure 3.2 Vaginal estrogen therapy reverses age-associated changes in reproductive tissues
(A) Experimental design depicting experimental strategy. (B) Serum estradiol of young (n=4),
aged (n=8), aged ovariectomized (n=10), and aged ovariectomized mice treated with vaginal
estrogen therapy (n=11). (C) Uterine horns of aged and aged VET mice, 4 weeks post ovariectomy.
(D) Images of unstained wet smears from aged and aged VET mice, 3 weeks following the start
of VET.
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Figure 3.3 Vaginal estrogen therapy reduces rUTIs and promotes terminal differentiation of
the aged urothelium
(A) Percentage of mice with positive UPEC urine titers >103 CFU/mL at given time points (aged
n=19-41, aged +VET n=14-24). (B) Quantification of QIRs in aged (n=28) versus aged +VET
(n=7) mouse bladders at 14 days post infection. (C) Quantification of p27kip1 positive nuclei in
aged (n=) and aged +VET mice, at 14 days post infection.

Figure 3.4 VET reverses age-associated upregulation of inflammatory genes
A) Heatmap of inflammation-related genes from young (n=4) and aged mice (n=4) from RNAsequencing analysis. (B-H) RT-qPCR analysis of inflammation-related genes B) IL-18r1, C) IL1β, D) Cd163l1, E) CD68, F) Clec4e, G) Tnfaip8l2, H) IL-4 from uninfected bladders of aged
(n=3-6) and aged +VET (n=3-6) mice.

Figure 3.5 VET induces partial regression of bladder tertiary lymphoid tissues in aged mice
(A) Tissue histology of aged and aged +VET mice, 3 weeks following VET treatment. Red
arrowheads denote bTLTs. Quantification of the number (B) and relative surface area (C) of
bladder tertiary lymphoid tissues in aged (n=44) and aged +VET (n=47) mice. RT-qPCR analysis
of uninfected bladder tissue TNF-α (D) and Cxcl13 (E) from aged (n=4-6) and aged +VET (n=4)
mice. (F) Serum Cxcl13 levels of aged (n=4) and aged +VET (n=3) mice.
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Figure 3.1: UPEC infection of aged mice results in increased urinary tract infection recurrence,
hyperinflammatory response, and reservoir formation
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Figure 3.4: VET reverses age-associated upregulation of inflammatory genes
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Chapter 4: A non-canonical autophagy-dependent role
of ATG16L1 T300A variant in urothelial vesicular
trafficking and uropathogenic Escherichia coli
persistence

This chapter was published in Autophagy 2019
Wang, Caihong et al. “A non-canonical autophagy-dependent role of the ATG16L1T300A variant
in urothelial vesicular trafficking and uropathogenic Escherichia coli persistence.” Autophagy vol.
15,3 (2019): 527-542. doi:10.1080/15548627.2018.1535290
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4.1 Abstract
50% of Caucasians carry a Thr300Ala variant (T300A) in the autophagy gene ATG16L1.
Here, we provide evidence that the T300A variant confers protection against urinary tract
infections (UTIs), the most common infectious disease in women. Using knock-in mice carrying
the human T300A variant, we show that the variant limits the principal-UTI-causing bacteria,
uropathogenic Escherichia coli (UPEC), from establishing persistent intracellular reservoirs,
which can seed UTI recurrence. This phenotype is recapitulated in mice lacking ATG16L1 or
ATG7 (both important for autophagosome formation) exclusively in the urothelium. We further
show that mice with the T300A variant exhibit urothelial cellular abnormalities, including
vesicular congestion and aberrant accumulation of uroplakin proteins. Importantly, presence of the
T300A variant in humans is associated with similar urothelial architectural abnormalities,
indicating an evolutionarily conserved impact. Mechanistically, we show that the reduced bacterial
persistence is independent of basal autophagic flux or proinflammatory cytokine responses to
infection and does not involve ATG14L1 or EPG5 (important in autophagy initiation and
autophagosome-lysosome fusion respectively). However, the T300A variant is associated with
increased expression of the small GTPase Rab33b, which specifically interacts with ATG16L1,
and other secretory Rabs (27b/11a) important for UPEC exocytosis from the urothelium. Finally,
inhibition of secretory Rabs in bladder epithelial cells via treatment with a pan-Rab prenylation
inhibitor increases intracellular UPEC load. Together, our results reveal that UPEC selectively
utilize genes important for autophagosome formation to persist in the urothelium; and that the
presence of the T300A variant in ATG16L1 is associated with changes in urothelial vesicle
trafficking, which disrupts the ability of UPEC to persist, thereby limiting the risk of recurrent
UTIs.
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4.2 Introduction
Autophagy is a housekeeping process that maintains cellular homeostasis through
recycling of nutrients and degradation of damaged or aged cytoplasmic contents. It involves a
series of dynamic membrane rearrangements that are mediated by a core set of autophagy (ATG)
proteins. Autophagosome formation starts with the stepwise engulfment of cytoplasmic material
by the phagophore, which later matures into a double-membrane-bound vesicle

1-5

. Vesicle

nucleation requires the activation of the class III phosphatidylinositol 3-kinase (PtdIns3K)
complex, whose activation depends on the formation of a complex that includes ATG14. The
vesicle elongation process involves two ubiquitin-like conjugation systems. The first involves the
covalent conjugation of ATG12 to ATG5, which then interacts non-covalently with ATG16-like 1
(ATG16L1). The second involves the conjugation of phosphatidylethanolamine (PE) to LC3 by
the sequential action of ATG3, ATG4, and ATG7. Autophagosomes then undergo maturation by
fusion with lysosomes to create autolysosomes, a process which requires EPG5 6,7.
Autophagy genes control bacterial infection and inflammation. Depletion or mutation of
autophagy genes is associated with inflammatory diseases in humans. For example, a single
nucleotide polymorphism (SNP, rs2241880, T300A variant) in ATG16L1 is present in 50% of
Caucasians and is associated with a higher risk of developing Crohn disease (CD, a form of
inflammatory bowel disease)

8,9

. ATG16L1 T300A variant does not affect basal autophagy but

affects unconventional autophagy and xenophagy (a specific form of autophagy targeting
pathogens10) and the inflammatory response to certain infections or metabolic stress signals11-16.
Autophagy is also involved in the pathogenesis of urinary tract infections (UTIs), one of
the most common, recurrent infectious diseases worldwide. UTIs afflict 150 million women per
year and recur in up to 40% of cases 17. The majority of infections are caused by uropathogenic
Escherichia coli (UPEC), which invade into superficial bladder epithelial cells, replicate, and
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persist therein a small number of urothelial cells as quiescent intracellular bacterial reservoirs
(QIRs) 18. QIRs are refractory to antibiotic therapies and do not elicit an active immune response
but can seed recurrent infections. UPEC are recognized by autophagy machinery and reside in
autophagosomal/lysosomal compartments
reduced UPEC persistence

20,21

19,20

; and mice hypomorphic for ATG16L1 have

. Furthermore, UPEC co-opt ferritinophagy, a selective form of

autophagy involved in iron release from ferritin stores, to survive and persist in bladder epithelial
cells 19. However, whether ATG16L1 deficiency-mediated protection from UTIs depends on the
canonical autophagy machinery or is specific to some other role for ATG16L1 is unclear.
Additionally, whether other autophagy pathway genes play a role in orchestrating the response to
UTIs remains to be elucidated. Further, given the important role of Atg16l1 in urothelial
intracellular membrane trafficking and UPEC persistence, it remains unknown whether the T300A
variant in Atg16l1 plays a role in pathogenesis of UTIs.
Superficial urothelial cells contain unique cytoplasmic organelles including fusiform
vesicles, which deliver preassembled uroplakin proteins to the apical cell surface during bladder
filling. Recent studies have demonstrated that specific small Rab GTPases (Rab27b and Rab11a)
are highly enriched in superficial urothelial cells and are important for vesicle trafficking,
uroplakin recycling22-27, and exosome-mediated expulsion of intracellular UPEC28-30.
Interestingly, network mapping of autophagy pathways has identified a Golgi-resident small
GTPase, Rab33b, which interacts directly with ATG16L1 and thereby modulates autophagosome
formation31. Whether the T300A variant is associated with changes to Rab33b or other Rabs
implicated in altered vesicular trafficking remains to be determined.
Here, we report that UPEC selectively utilize autophagy genes important for
autophagosome formation to persist in the urothelium. T300A mice carrying the human mutant
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allele in the ATG16L1 gene exhibit altered urothelial architecture and harbor significantly fewer
persistent bacterial reservoirs in the urothelium. Importantly, this feature is conserved in humans
with the rs2241880 GG genotype (homozygous for the T300A variant in human ATG16L1), who
appear to suffer from fewer recurrent UTIs. We demonstrate that these effects are independent of
the canonical autophagy pathway and bladder mucosal immunity; but appear to be associated with
increased expression of small Rab GTPases that are known to be important for UPEC expulsion.
Thus, the T300A variant protects the bladder mucosa from persistent UTI infection.

4.3 Results
4.3.1 Presence of Atg16l1 T300A variant confers protection from UPEC persistence in
urothelium
We first sought to determine whether the T300A variant of ATG16L1 was sufficient to
confer protection from UPEC persistence in the bladder epithelium, a phenotype observed in mice
with reduced ATG16L1 (Atg16l1HM)21. We induced UTIs in adult female wild type (WT) and
Atg16l1 T300A mice and quantified the number of QIRs at 14 days post infection (dpi) (Figure
4.1A). Urothelial cells of T300A mice harbored significantly fewer QIRs than did those of WT
mice (Figure 4.1D-E). To confirm that the reduced QIR formation was not due to reduced UPEC
invasion or defects in early colonization, we measured bacterial titers in the urine and bladder at
24 hours post infection (hpi) and found comparable bacterial titers between WT and Atg16l1
T300A mice (Figure 4.1B-C). Thus, the T300A variant specifically confers increased resistance
to UPEC persistence but does not affect UPEC invasion or early colonization unlike what was
noted in Atg16l1HM mice21.
4.3.2 The T300A variant is sufficient to induce urothelial cellular architectural alterations
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In a healthy bladder, the plasma membranes of superficial luminal epithelial cells contain
hexagonal arrays of uroplakin proteins, which are transported by discoidal storage vesicles and
multivesicular bodies (MVB) and are critical for normal epithelial flexibility and barrier function
32,33

. Previous work has demonstrated a role for ATG16L1 in superficial cell vesicular trafficking

in mice globally hypomorphic for ATG16L1 (Atg16l1HM mice)21. We next sought to determine
whether the T300A variant was sufficient to confer the vesicular phenotype associated with
decreased UPEC resistance. Indeed, we found substantially more multivesicular bodies (MVBs)
and lysosomes in T300A mice vs. those of WT mice (Figure 4.2A-B). Blinded analysis of sections
revealed that 90% of T300A mice had aberrant vesicle congestion in superficial cells, whereas
only 7% of WT mice had this phenotype (Figure 4.2C). Transmission electron microscopy (TEM)
and Immunofluorescence (IF) analysis confirmed that the density of MVBs, lysosomes, and
uroplakin expression in urothelial cells was significantly higher in T300A mice than in WT mice
(Figure 4.2D-I). These observations indicate that the human SNP T300A variant is sufficient to
disrupt urothelial cellular architecture in mice.
4.3.3 UPEC hijacks a specific set of autophagy genes important for normal tissue
architecture for intracellular persistence in the bladder
We next examined if the T300A variant-conferred restriction of UPEC persistence and
urothelial architectural changes were unique to ATG16L1 or a shared feature with other canonical
autophagy genes. First, we depleted key genes for each step of the autophagy pathway via short
interfering RNA (siRNA) mediated gene-silencing in bladder epithelial cells (BECs). RT-qPCR
and immunoblotting were performed to validate the knock down of mRNA levels of ATG16L1,
ATG7, ATG14L1 and EPG5 and protein levels of ATG16L1 and ATG7(Fig S1). We confirmed
that silencing of ATG16L1 led to a significant reduction in the intracellular bacterial load in bladder
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epithelial cells (BECs) at 3 and 6 hpi (Figure 4.3A). The effects were phenocopied in ATG7
deficient cells (Figure 4.3B). In contrast, knockdown of ATG14L1 and EPG5 did not decrease
UPEC intracellular bacterial load (Figure 4.3C-D). We did not observe significant differences in
bacterial load at earlier time points (0.5h and 1 hpi) in cells depleted for ATG16L1 or ATG7,
indicating that these genes are not required for early invasion and colonization. Crystal violet
assays did not reveal significant changes in cell growth in ATG16L1 or ATG7 deficient cells,
indicating that the observed reduction in the intracellular load of UPEC was not likely due to
decreased cell viability (Fig. S2).
To extend the in vitro findings, we systematically examined whether loss of autophagy
genes specifically in the urothelium affects UPEC persistence. To generate urothelial-cell-specific
knockouts, we crossed Atg16l1fl/fl, Atg7f/fl, and Atg14l1fl/fl mice to Upk3a–GFP-cre-ERT2 mice,
which drive deletion exclusively in superficial urothelial cells34 . We examined bladders of mice
globally deficient in Epg5, a gene important for autophagosome/lysosome fusion. Next, we
induced UTIs in Atg16l1fl/fl;Upk3a-cre+, Atg7fl/fl;Upk3a-cre, Atg14l1fl/fl;Upk3a-cre+ and Epg5 -/mice and examined urine bacterial loads in these mice at 24 hpi and quantified the number of
bacterial QIRs at 14 dpi. We found that loss of each of the genes had no effect on bacteriuria at 24
hpi (Figure 4.4A-D). However, at 14dpi, Atg16l1fl/fl; Upk3a-cre+ and Atg7fl/fl;Upk3a-cre+ mice
harbored significantly fewer QIRs in the bladder than their Cre- littermates (Figure 4.4E-F), an
effect not seen following loss of Atg14l1 in urothelial cells or global deletion of Epg5 (Figure
4.4G-H). Together, these data indicate that UPEC co-opts proteins of the elongation phase of the
autophagy pathway important for autophagosome formation for persistence in QIRs but does not
require proteins governing the initiation or autophagosome-lysosome fusion phases.
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To determine if depletion of ATG16L1 specifically in the urothelium was sufficient to alter
urothelial architecture, we examined bladders from Atg16l1fl/fl; Upk3a cre+ mice with TEM and
IF. We observed that these mice also display the vesicular congestion phenotype, characterized by
accumulation of MVBs and lysosomes (Figure 4.5A), which have been documented in the
Atg16l1HM mice21 and in the T300A mice as shown above. Previously, it has been shown that loss
of Atg16l1 in the myeloid compartment or in the adaptive immune compartment did not alter
urothelial cellular architecture, supporting that the structural changes were epithelial-intrinsic21.
To further examine if other autophagy proteins were also involved, we examined urothelial
architecture in Atg7fl/fl; Upk3a cre+, Atg14l1fl/fl;Upk3a cre+ mice and Epg5

-/-

mice by IF and

TEM. We found that only mice with urothelial cells lacking ATG7 showed similar vesicular
congestion seen with loss of ATG16L1 (Figure 4.5B). Blinded quantification revealed that
whereas 34% of Atg16l1fl/fl; Upk3a cre+ mice and 55% of Atg7fl/fl; Upk3a cre+ mice had vesicle
congestion in superficial cells, only 7% of Atg16l1 fl/fl and 22% of Atg7fl/fl Cre negative controls
showed this phenotype. TEM analysis corroborated these findings (Figure 4.5A-B and Fig S3).
Vesicular congestion was not seen in superficial cells from Atg14l1fl/fl; Upk3a cre+ and Epg5

-/-

mice (Figure 4.5C-D and Fig S3). Together, our data reveal a role for ATG16L1 and ATG7 but
not ATG14L1 or EPG5 in regulating both UPEC persistence in bladder epithelial cells as well as
cellular membrane trafficking that is known to be important for bacterial persistence.
4.3.4 Decreased UPEC persistence in Atg16l1 T300A urothelium is independent of innate
immune responses in the bladder mucosa
Recent studies in the intestinal mucosa have shown that the T300A variant sensitizes mice
to cellular stress induced by intestinal infections with Salmonella typhimurium and Yersinia
enterocolitica, in large part due to increased ATG16L1 cleavage by the apoptotic proteases,
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caspase 3 and caspase 712,13. Here, we found that levels of caspase 3 were equivalent in urothelium
of WT and T300A mice before infection (Figure 4.6A) and at 3 and 6 hpi (Figure 4.6B-C). Next,
we determined whether T300A variant-mediated resistance to UPEC persistence was associated
with infiltration of innate immune cells into the bladder. We found that the urines of infected
T300A mice harbored similar numbers of neutrophils and monocytes upon infection as did WT
mice (Figure 4.6D). Previous studies have shown that deletion of ATG16L1 in macrophages
amplifies inflammatory IL-1β signaling in response to bacterial lipopolysaccharide or UPEC 35,36.
However, we found that bone-marrow-derived macrophages from T300A mice produced similar
levels of IL-1β, IL-6 and TNF-α (Figure 4.6E-G) in response to UPEC infection as those from
WT mice. Further analysis of mRNA levels of IL-1β, IL-6 and TNF-α from bladders at 24 hpi did
not show a significant difference between WT and T300A mice (Figure 4.6 H-J). Together, these
data suggest that the T300A variant does not elicit an elevated inflammatory cellular influx or
inflammatory cytokine response upon UPEC infection.
4.3.5 Atg16l1 T300A variant does not affect bulk autophagy in the bladder
We next reasoned that, if ATG16L1 is critical for bacterial persistence in the bladder, then
the T300A variant may cause decreased persistence by affecting ATG16L1 protein expression or
autophagic activity in the bladder. However, we found that levels of ATG16L1 in WT and T300A
mouse bladders before infection (Figure 4.7A) or after infection (Figure 4.7B), are
indistinguishable indicating that stability of ATG16L1 is not decreased in T300A mice. Next, to
examine autophagic activity, we measured levels of LC3-II before and after starving WT and
T300A mice for 24 hours. Although the LC3-II to LC3-I ratio increased upon starvation in both
WT and T300A mice, we detected no differences in LC3-II levels between the two genotypes
(Figure 4.7C). To examine whether the T300A variant impaired autophagy during a UTI, we
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measured LC3-II at 3 hpi and found equivalent levels of LC3-II between bladders from WT and
T300A mice (Fig.7D). Thus, the T300A variant does not alter bulk autophagy activity in the
bladder.
4.3.6 The presence of T300A variant alters expression of ATG16L1-associated Rab GTPase
33b and other Rabs important for UPEC expulsion
Collectively, our findings suggest that the intersection of UPEC with the autophagy
machinery occurs at the autophagosome formation phase wherein ATG16L1 plays a critical role
as a central adaptor

37,38

. Given the important role of ATG16L1 in urothelial intracellular

membrane trafficking and UPEC persistence, we sought to investigate how the T300A variant
might alter the Rab GTPase network in the urothelium. Network mapping of autophagy pathways
has identified proteins, notably, a Golgi-resident small GTPase, Rab33b, which interacts directly
with ATG16L1 and modulates autophagosome formation31,39,40. Thus, we hypothesized that
Rab33b could be implicated in the altered UPEC pathogenesis in T300A mice. To test this, we
examined expression levels of Rab 33b in WT and T300A bladders before and after UPEC
infection. Before infection, we found no significant change in expression levels of Rab 33b.
However, upon induction of a UTI, we noted highly significant changes in Rab33b expression in
the T300A bladders (Figure 4.8A), wherein the variant was associated with an increase in Rab33b
expression in contrast to its down regulation in WT controls. Recent studies have demonstrated
that specific small secretory Rab GTPases, Rab27b and Rab11a are highly enriched in superficial
urothelial cells and are important for vesicle trafficking, uroplakin recycling, and expulsion of
intracellular UPEC22-30. Examination of Rab27b and Rab11a expression in WT and T300A mice
revealed that the T300A-variant was associated with increases in expression levels of both Rabs
upon induction of a UTI. Thus, secretory Rabs associated with ATG16L1 and autophagosome
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formation and/or uroplakin recycling appear to be altered in T300A mice, a result consistent with
a role for this variant in modulating urothelial architecture.
Given the established role of Rab27b and Rab11a in urothelial stretch induced trafficking2426

and in UPEC exocytosis from BECs28,29, we mechanistically determined whether inhibition of

Rab activity would lead to increased bacterial load in BECs. We treated BECs with 3-Pyridinyl
ethylidene hydroxyl phosphonocarboxylate (3-PEHPC), an inhibitor of Rab geranylgeranyl
transferase that inhibits all secretory Rab GTPase activity41-43. Pretreatment of BECs with 3PEHPC prior to infection with UPEC revealed a significant increase in intracellular bacteria load
upon infection (Figure 4.8B). The highest load was noted at 6 hpi, which corresponds to the time
point shown to be the peak of exocytosis of UPEC through Rab27b29. Taken together, our in vivo
and in vitro data suggest that changes in Rab27b/11a and 33b levels due to the presence of T300A
variant may affect UPEC expulsion and thereby lead to reduced UPEC persistence in urothelium.
4.3.7 Humans carrying the ATG16L1 T300A variant display aberrant urothelial cell
architecture in bladder tissue biopsies and reduced incidence of recurrent UTIs
Given that UPEC persistence correlates with urothelial-specific aberrant vesicular
trafficking (and not with canonical autophagy pathways or non-cell-autonomous immune cell
effects) in mice carrying the human T300A variant, we next determined whether the incidence of
the T300A variant in human populations would be correlated with similar urothelial architectural
alterations. We obtained bladder tissues from patients undergoing transurethral resections for
bladder cancer diagnosis and examined them in a blinded fashion for presence/absence of vesicles.
Remarkably, our analysis revealed that 33% of individuals with the GG (homozygous carriage of
the T300A allele) or AG (heterozygous) genotypes displayed urothelial vesicular congestion,
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whereas only 14% of those with the AA (homozygous for the WT ATG16L1 allele) genotype had
this phenotype (Figure 4.9A-C).
Given the significant relationship in mice and human bladders between carriage of the
T300A variant and urothelial structural abnormalities and protection from UPEC persistence in
mice, we sought to evaluate whether the T300A variant was associated with UTI incidence in a
human population cohort of inhabitants of Nijmegen in the Netherlands, as part of the Nijmegen
Biomedical Study (n= 2,102 subjects, two cohorts). Univariable logistic regression analyses and
multivariable logistic regression analyses showed that in women who experienced at least one UTI,
those with the GG genotype were less likely to experience three or more UTIs than those with the
AA genotype (Supplemental Table 1). Additionally, among the men who experienced at least
one UTI, those with the GG genotype were less likely to experience three or more UTIs than those
with the AA genotype (Supplemental Table 2). The clinical findings are not statistically
significant, and do not indicate a cause and effect relationship due to sample size considerations
and given that most of the UTIs (particularly in the women) were self-diagnosed. Nevertheless,
the strong association between the presence of the T300A variant and increased urothelial vesicular
abnormalities in mouse and human bladder urothelium indicates a key role for the T300A variant
in the bladder mucosa.
4.4 Discussion
In this report, we demonstrated that the common ATG16L1 T300A variant confers
protection from UPEC persistence principally due to alteration in urothelial cell architecture and
consequent depletion of UPEC-protective niches. We found that mice carrying the human
ATG16L1 T300A variant phenocopied urothelial abnormalities noted in mice carrying a
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hypomorphic allele of Atg16l1 (Atg16l1HM) with

an 80% knockdown of the protein. Both

Atg16l1HM and T300A mice harbored fewer persistent UPEC reservoirs than WT mice,
underscoring a pro-pathogenic role for ATG16L1 in the bladder mucosa.
Interestingly, we observed substantial differences at the early stages of UPEC infection
between Atg16l1HM and T300A mice. In T300A mice, as opposed to ATG16L1 HM mice, we did
not observe faster clearance in the urine, increased neutrophil infiltration, or increased IL-1β
production by macrophages. This is likely due to the means of generation of these mice.
Atg16L1HM mice were generated using gene-trap mutations to introduce a false splice acceptor in
the intronic regions adjacent to exon 6 or 10, resulting in truncated core protein. On the other hand,
the T300A mutation occurs in the WD repeat C-terminal domain of ATG16L1 which is not
associated with canonical autophagy12,13. Our study demonstrated that T300A-associated
urothelial alterations are independent of bulk autophagy activity, which is consistent with previous
findings that the ATG16L1 T300A variant does not reduce basal autophagy14-16. Boada-Romero et
al., recently showed that the ATG16L1 T300A variant also alters the ability of the WD repeat
domain to interact with a transmembrane protein, TMEM59 and thereby affects TMEM59mediated endosome trafficking. This impairment does not affect canonical autophagy and does
not require caspase processing of ATG16L111. Our findings are consistent with these observations
because the presence of T300A variant does not sensitize caspase-dependent cleavage of
ATG16L1 upon UPEC infection. In other words, the level of ATG16L1 in the bladder of T300A
mice is not affected.
T300A mice exhibited alterations in the recycling of intracellular membranes in superficial
urothelial cells, increased expression of uroplakins, and accumulation of MVBs, which is
consistent with an important role of ATG16L1 in governing the secretory pathway in epithelial
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cells 12,21,44. Because MVBs are required for degradation and recycling of uroplakins45, we suggest
that accumulation of MVBs in the urothelium may impair intracellular trafficking of uroplakins
and UPEC such that the bacteria are rerouted to exosomes for exocytosis

29

rather than to

autophagosomes where they can persist. Recent work by Miao, et al., has demonstrated that
concerted actions of the secretory Rab GTPases, Rab11a and Rab27b are involved in expulsion of
UPEC from bladder epithelial cells28. Indeed, our findings that the T300A variant was associated
with increases in Rab27b, Rab11a and a notable increase in ATG16L1-associated Rab, Rab 33b,
which may explain the reduced UPEC persistence in T300A bladders. This notion is further
underscored since bladder epithelial cells treated with a pan-secretory Rab inhibitor harbour
significantly higher intracellular UPEC loads. Further work with targeted deletion of specific Rabs
is needed to determine how ATG16L1 interacts with Rabs or other pathways shown to regulate
membrane trafficking processes. Further mechanistic studies are needed to understand how
ATG16L1 deficiency or T300A polymorphism alters MVB formation and trafficking and how this
may be mediated via Rab33b or 27b. Nevertheless it is clear that this variant is associated with
decreased UPEC persistence, likely via disruption of UPEC trafficking to autophagosomes where
they are able to persist. Our findings are similar to a recent study demonstrating that the T300A
variant is associated with structural defects in Paneth cells caused by defects in secretory
autophagy due to the presence of this variant. Interestingly, the consequences of T300A variantinduced structural defects in Paneth cells and superficial bladder cells are quite the opposite. Bel
et al., showed that disrupted secretory autophagy in Paneth cells in T300A mice was associated
with increased Salmonella typhimurium infection46. However, in the bladder, T300A variantinduced structural changes are beneficial to the host as these alterations impair the ability of UPEC
to persist in the urothelium. Thus, our data highlight a positive role for secretory autophagy in
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response to uropathogenic infection and point towards the tissue- and cell-type-specific roles of
the T300A variant.
We demonstrate that UPEC adopts a unique strategy by selectively exploiting a specific
set of autophagy genes to establish latency, confirming that bacterial pathogens can utilize
different host cell compartments/pathways during their intracellular cycle. Autophagy genesdependent cellular functions in controlling intracellular pathogens have been reported in a variety
of disease models. For example, Starr, et al. showed selective subversion of autophagy initiation
proteins by Brucella abortus47. Huang, et al., showed that IFN-γ inhibits murine norovirus growth
in macrophages in a manner dependent on Atg5, Atg7, and Atg16l1, but not on Atg14l1 48. More
recently, Park, et al. showed that loss of autophagy genes including Atg5, Atg16l1, Atg7 and
Atg14l1 but not Atg4b in myeloid cells resulted in inhibition of MHV68 reactivation from latently
infected macrophages 49. Additionally, Kimmey, et al., demonstrated a unique role for Atg5 but
not for other autophagy genes in modulation of M. tuberculosis infection50. The exact mechanism
by which UPEC hijacks ATG16L1 and ATG7 and the bacterial proteins that are involved in
mediating this process remain poorly described.
We suggest that the absence of ATG16L1 or ATG7 leads to alteration of intracellular
membrane trafficking, which in turn reroutes UPEC to compartments where they cannot persist.
Urothelium-specific loss of autophagy genes appears sufficient to induce urothelial vesicular
congestion and confer resistance to UPEC persistence, further supporting our conclusion that
regulation of QIR formation is not governed by loss-of-autophagy genes-mediated systemic
inflammation. However, loss of autophagy genes in myeloid cells or in the adaptive immune
compartment does not affect intracellular membrane trafficking or bacterial persistence within the
urothelium 21. Furthermore, we had previously reported that Atg16l1HM macrophages had increased
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caspase-1 dependent secretion of IL-1β upon UPEC infection36. Likewise, recent studies showed
that the T300A polymorphism was associated with increased IL-1β production in macrophages
due to increased caspase-3-mediated degradation of ATG16L1 in the context of metabolic stress
or infection

12,13

. However, we did not find any differences in production of IL-1β or other

proinflammatory mediators between macrophages from Atg16l1 T300A or WT mice before or in
response to UPEC infection. Together, our findings suggests that the T300A variant specifically
affects urothelial cells and indicate an epithelial-intrinsic role of autophagy genes in intracellular
trafficking of UPEC inside the urothelium.
It is remarkable that presence of this variant in humans with no bladder disease, is sufficient
to confer structural differences in urothelial cells. UTIs have been described as early as 1550 B.C.,
are the second most common infection in humans, and the most common infection in women
worldwide each year. Population cohort studies of Caucasian men and women in the Netherlands
examining carriage of the T300A variant and incidence of recurrent UTIs, while not conclusive,
hint at an inverse correlation leading us to speculate that the T300A variant of ATG16L1 may be
prevalent in the population, in part, because it is protective against a common infectious disease.
This model is reminiscent of the observation that the harmful sickle cell trait is maintained in
humans because it confers resistance to another common infection, malaria, by structurally altering
red blood cells, thus limiting the ability of the parasite to invade
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. Together, our findings

underscore a key role for ATG16L1 and its associated human polymorphism, T300A, in
maintaining bladder epithelial architecture and altering the trafficking patterns of intracellular
UPEC, thus having significant clinical implications for understanding the etiology of recurrent
UTIs.
4.5 Experimental Procedures
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Mice
Atg16l1fl/fl and Atg14l1fl/fl mice were kindly provided by Dr. Herbert Virgin. Atg7fl/fl mice were a
kind gift from Dr. Masaaki Komatsu. Upk3a –GFP-cre-ERT2 mice were purchased from Jackson
laboratory. Atg16l1fl/fl, Atg7fl/fl or Atg14l1fl/fl mice were bred to Upk3a –GFP-cre-ERT2

mice to

generate Atg16l1fl/fl, Atg7fl/fl or Atg14l1fl/fll;Upk3a cre-ERT2 mice. Atg16l1fl/fl;Upk3a cre+,
Atg7fl/fl;Upk3a cre+ or Atg14l1fl/fll;Upk3a cre+ mice and their Cre- counterparts were treated with
tamoxifen (1mg/20 gram body weight) intraperitoneally 3 times over the course of 1 week. The
mice were then infected 1 week after last tamoxifen treatment. Epg5-/- mice were kindly provided
by Dr. Hong Zhang
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. Atg16l1 T300A mice were generated as described12. Experiments were

performed according to approved protocols. In all experiments, adult female mice, 8-10 weeks of
age were used. Mice were maintained under specified pathogen-free conditions in a barrier facility
and under a strict 12 hr light/dark cycle. All experimental procedures were approved by the animal
studies committee of the Washington University School of Medicine (Animal Welfare Assurance
#A-3381-01).
Bacterial Strains, mouse inoculations, and urinalysis.
UTI89, a clinical UPEC isolate was grown statically for 17 h in Luria-Bertani (LB) broth at 37°C
prior to infection in all studies21. Mice were anesthetized and inoculated via transurethral
catheterization with 107 colony forming units (CFU) of UTI89 in phosphate-buffered saline (PBS).
Urine and bladders were collected at 24hpi to measure bacterial titres. Bladders were collected
before infection and at indicated time points (3-24hpi for acute stage of infection and 14 dpi for
persistent stage) following bacterial inoculation.
Quantification of QIRs
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Mice were sacrificed at 14 dpi and the bladders were processed as described previously 21. Eight
separate 5 µm step sections over a thickness of 300 µm were immunostained with antibodies
against E. coli, Lamp1, and E-cadherin. The total number of Lamp1-positive UPEC reservoirs
were counted using a 63x oil objective on a Zeiss Apotome microscope and reported as number of
QIRs/bladder.
Immunofluorescence and immunoblotting analysis
Mouse bladders were processed as described previously 21. The following primary antibodies were
used: rabbit polyclonal antibodies to E. coli (United States Biological; Swampscott, MA), mouse
monoclonal antibody to E-cadherin (BD Bioscience; San Jose, CA), rat monoclonal antibody to
Lamp1 (clone ID4B; Developmental Studies Hybridoma Bank, NICHD; Bethesda, MD), and
mouse anti-uroplakin III (Fitzgerald, Acton, MA). Antigen-antibody complexes were detected
with Alexa Fluor 488-, 594-, and 647-conjugated secondary antibodies (Invitrogen; Carlsbad, CA).
Images were obtained on a Zeiss Apotome microscope using 10-20x and 40-63x (oil) objectives.
Blots were probed with the following primary antibodies: rabbit polyclonal to ATG16L1 (Abgent,
San Diego, CA), LC3, and Caspase3, and rabbit monoclonal to GAPDH (Cell Signaling, Danvers,
MA). Secondary antibodies used were goat anti-rabbit IgG-HRP and donkey anti-goat IgG-HRP
(Santa Cruz, Dallas, Texas). The protein bands on the developed film were quantified by Image J
(NIH: http://rsb.info.nih.gov/ij/).
Transmission electron microscopy (TEM) and measurement of organelle density
Bladders were fixed with fixative containing 2% glutaraldehyde and 3% PFA in 0.1M sodium
cacodylate. Samples were rinsed three times in sodium cacodylate buffer and post-fixed in 1%
osmium tetroxide for 1hr, stained in 1% uranyl acetate for a further hour, then rinsed, dehydrated,
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and dried using critical point drying. Samples were then gold-coated and viewed in an ULTRA 55
FEG (ZEISS). TEM images were taken from the superficial cells area at 2500X. The number of
lysosomes and MVBs and the surface area of the superficial cells was counted by Image J. The
density of MVBs and lysosome was reported as the number of MVBs and lysosomes per surface
area examined (n=200-300 TEM sections from 3 mice).
Quantitative PCR (qPCR)
Bladders from WT and T300A mice were collected before and 24 hours post infection. RNA was
isolated from bladder tissue using TRIzol (Invitrogen, Carlsbad, CA) and treated with DNase I
(Ambion, Austin, TX) to remove contaminating DNA. cDNAs were synthesized from 1 µg of total
RNA using Superscript II RNase H reverse transcriptase (Invitrogen, Carlsbad, CA). Gene
expression was detected by real-time PCR using an CFX 96 Real-Time System(Bio-Rad, Hercules,
CA) and SYBR green PCR master mix (Bio-Rad, Hercules, CA). Each sample was measured in
triplicate. Relative quantification was determined by using the comparative threshold cycle (CT)
method with 18S expression as a control.
Neutrophil and monocyte counts in urine
Urine samples were collected before and 24 hours after infection. HEMAVET® 950, Veterinary
5 part WBC Hematology System (Americas Drew Scientific Inc, Waterbury, CT) (Department of
Comparative Medicine, WUSM) was used to determine neutrophil and monocyte counts.
Isolation, differentiation and challenge of bone marrow-derived macrophages (BMDMs)
Differentiation of BMDMs from Atg16l1 T300A and WT mice was performed as described
previously36. Briefly, bone marrow was aseptically isolated and differentiated on non-tissue-
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culture-treated petri dishes for 7 days at 37°C with 5% ambient CO2 in DMEM with 15% FBS,
30% L929-conditioned media, 1% Glutamax, 1% Na-Pyruvate, and 1% Penicillin and
Streptomycin. On day 7 post-isolation, non-attached cells were aspirated, and the media was
changed to DMEM with 10% FBS, 1% Glutamax, and 1% Na-Pyruvate. On day 8, cells were
incubated with ice-cold DPBS, removed with a cell scraper, counted, and plated at 5x105 cells/ml.
On day 9, BMDMs were challenged with an MOI of 0.1 of UTI89. BMDMs were incubated with
UTI89 for 2 hours, treated with medium containing 100 µg/ml gentamicin for 1 hour, and then
incubated with medium containing 10 µg/ml gentamicin for 21 hours. Then, the supernatant was
collected for ELISAs. DuoSet ELISA kits for IL-1b, IL-6, and TNFa (R&D systems, Minneapolis,
MN) were used according to the manufacturer's instructions.
Cell culture, bacterial infection, and gentamycin protection assays
Bladder epithelial cell line, 5637 (BECs) (ATCC HTB-9) were used for all experiments. BECs
were seeded into 24-well plates and grown to confluency in RPMI 1640 medium(GIBCO)
supplemented with 10% fetal bovine serum (Sigma), infected with UTI89 at a multiplicity of
infection of 1:100 and incubated for 1 h at 37°C. Extracellular bacteria were then removed from
the BECs by washing twice with phosphate-buffered saline (PBS) and incubating with medium
containing 0.1 mg/mL gentamycin. At the indicated times, BECs were washed three times in PBS
and lysed in 1 ml of PBS containing 0.1% Triton X-100. Lysates were plated on LB agar plates
to determine numbers of surviving intracellular bacteria.
siRNA transfection
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BECs were transfected using Trans-X2 (Mirus) reagent with siRNA targeting ATG16L1
(IDs30071), ATG7 (IDs20651), ATG14L1 (ID22135), EPG5 (ID148797) or non-targeting control
siRNA (4390844) (Life Technologies, Carlsbad, CA).

Rab inhibitor studies
3-Pyridinyl ethylidene hydroxyl phosphonocarboxylate (3-PEHPC), an analog of the
bisphosphonate drug risedronate was generated as previously described42,43. 5637 cells were
treated with 5 mM 3-PEHPC for 24 hours before being infected with UPEC. The cells were
collected at 0.5, 3 and 6hpi for quantification of intracellular bacterial load using gentamicin
protection assay.
Tissue analysis of human bladder biopsy samples
Paraffin-embedded bladder biopsy samples from patients who underwent transurethral tissue
resections were retrieved from the Pathology service of Barnes-Jewish Hospital, St. Louis, MO.
All samples were de-identified, and tissues with pathological evidence of malignancy were
excluded as intact superficial urothelial cells were not evident. Tissues were sectioned and stained
with hematoxylin & eosin and screened in a blinded manner for vesicular congestion by bright
field differential interference contrast microscopy at 40X and 100X magnification. The
presence/absence of vesicles was scored. Images were acquired with Olympus DP71 software.
rs2241880 genotyping
Genomic DNA was extracted from paraffin-embedded bladder sections using the QIAamp DNA
FFPE Tissue Kit. Genotyping to detect the rs2241880 polymorphism in ATG16L1 was performed
using the TaqMan 5´-exonuclease allelic discrimination assay, which contains sequence-specific
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forward and reverse primers to amplify the polymorphic sequences and two probes labeled with
VIC and FAM dyes to detect both alleles of each polymorphism. PCR reactions were carried out
with TaqMan universal PCR Master Mix following the manufacturer’s instructions in a Step-One
Plus Real-time PCR system.
Statistical analyses
To assess the significance of differences between mouse groups, unpaired t-test or non-parametric
Mann-Whitney U tests were performed with Graph Prism software. P<0.05 was considered
significant.
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4.7 Figure Legends and Figures
Figure 4.1. Mice carrying the Atg16l1 T300A variant exhibit reduced UPEC persistence: (A).
Schematic of experimental setup. (B) Colony forming unit (CFU) counts of bacteriuria at 24 hpi
plotted as mean of the Log10 value. n=19 for WT; n=45 for T300A mice; n=6 experiments. Ns,
not significant by Mann-Whitney test. (C). CFU counts of the bladder plotted as mean ± SD of the
Log10 value at 24 hpi. n=5 for WT; n=4 for T300A mice. Ns, not significant by Mann-Whitney
test. (D). Quantification of QIRs in WT and T300A bladders at 14 dpi. n=8 sections/bladder, n=1745 mice/genotype. *P<0.05 by Mann-Whitney test. (E) IF image of a bacterial QIR. Bar=10 µm.

Figure 4.2 Atg16l1 T300A variant mice exhibit superficial cell architectural changes: (A-B)
IF imaging analysis of urothelium from WT (A) and Atg16l1 T300A (T300A) (B) mice. Green,
vesicles; magenta, E-cadherin; blue, biz-benzimide DNA stain; red arrowhead, vesicular
congestion. Bar=10 µm. (C) Percentage of WT and T300A mice that showed vesicular congestion.
(D-E) TEM of superficial cell ultrastructure in WT (D) and T300A (E) mice. Red arrowhead,
multi-vesicular bodies; blue arrow, lysosomes. Bar=1 µm. (F-G) Quantification of MVBs (F) and
lysosomes (G) in TEM images of WT and T300A urothelium. Bars represent mean ± SEM. n=3
mice.*P<0.05 by unpaired two-tailed T test. (H-I) IF of uroplakin (green) in bladders of WT (G)
and T300A (H) mice. Blue, bis-benzimide. Bar=10 µm.

Figure 4.3 Loss of ATG16L1 or ATG7 but not ATG14L1 or EPG5 leads to decreased
intracellular UPEC growth in BECs. Quantification of intracellular UPEC CFU in BECs treated
with control siRNA and ATG16L1 siRNA (A), ATG7 (B), ATG14L1(C) and EPG5 (D), Bars
represent mean ± SD. *P<0.05 by Mann-Whitney test, n=3 replicates.
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Figure 4.4 Loss of Atg16l1 or Atg7 in urothelium but not Atg14l1 or Epg5 leads to significant
reduction in QIR formation: (A-D) CFU counts of bacteriuria at 24hpi plotted as mean ± SEM
of the Log10 value in Atg16l1fl/fl;Upk3a cre+ and Atg16l1fl/fl;Upk3a cre- mice (A), Atg7fl/fl;Upk3a
cre+ and Atg7fl/fl;Upk3a cre - mice (B), Atg14l1fl/fl;Upk3a cre+ and Atg14l1fl/fl;Upk3a cre- mice
(C) and WT and Epg5

-/-

mice (D). Ns, not significant by unpaired two-tailed T test. (E-H)

Quantification of QIRs in Atg16l1fl/fl;Upk3a cre+ and
Atg7fl/fl;Upk3a cre+ and Atg7fl/fl;Upk3a creAtg14l1fl/fl;Upk3a cre-

bladders

Atg16l1fl/fl;Upk3a cre- bladders (E),

bladders (F), Atg14l1fl/fl;Upk3a cre+ and

(G) and WT and Epg5

-/-

bladders (H) at 14 dpi. n=8

sections/bladder, n=18-25 mice/genotype. Bar shows Mean ±SD. *P<0.05 by Mann-Whitney test,
ns, not significant.

Figure 4.5 Loss of Atg16l1 or Atg7 but not Atg14l1 or Epg5 leads to urothelial architecture
alterations: (A1,2-D1,2) IF imaging analysis of urothelium from Atg16l1fl/fl;Upk3a cre+ and
Atg16l1fl/fl;Upk3a cre-

(A1-A2), Atg7l1fl/fl;Upk3a cre+ and Atg7fl/fl;Upk3a cre - (B1-B2),

Atg14l1fl/fl;Upk3a cre+ and Atg14l1fl/fl;Upk3a cre- (C1-C2) and WT and Epg5 -/- mice (D1-D2).
Green, vesicles; magenta, E-cadherin; blue, biz-benzimide DNA stain; red arrowhead, vesicular
congestion. Bar=10 µm. (A3, 4-D3,4) TEM of superficial cell ultrastructure in Atg16l1fl/fl;Upk3a
cre+ and Atg16l1fl/fl;Upk3a cre- (A3-A4), Atg7fl/fl;Upk3a cre+ and Atg7fl/fl;Upk3a cre - (B3-B4),
Atg14l1fl/fl;Upk3a cre+ and Atg14l1fl/fl;Upk3a cre- (C3-C4) and WT and Epg5 -/- mice (D3-D4).
Red arrowhead, multi-vesicular bodies; blue arrow, lysosomes. n=3 mice. Bar=2 µm. (A5-D5)
Quantification of MVBs of Atg16l1fl/fl;Upk3a cre+
Atg7fl/fl;Upk3a cre+ and

and Atg16l1fl/fl;Upk3a cre-

(A5),

Atg7fl/fl;Upk3a cre -. (B5), Atg14l1fl/fl;Upk3a cre+ (C5) and Epg5 -
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/-

mice (D5) urothelium. Bars represent mean ± SEM. (A6-D6) Quantification of lysosomes of

Atg16l1fl/fl Upk3a cre+ and Atg16l1fl/fl;Upk3a cre- (A6), Atg7fl/fl;Upk3a cre+ and Atg7fl/fl;Upk3a
cre (B6), Atg14l1fl/fl;Upk3a cre+ and Atg14l1fl/fl;Upk3a cre-

(C6) and WT and Epg5

-/-

mice

urothelium (D6). Bars represent mean ± SEM.
Figure 4.6 Atg16l1 T300A variant does not affect cytokine response to UPEC infection: (AC) Western blot detection of caspase 3 in whole bladder protein from WT and T300A mice before
infection (A), 3 hpi

(B), and 6 hpi (C). Number below the blots showing densitometry

quantification of the blots. (D) Neutrophil and monocyte counts in the urine at 24hpi. n=4-5
mice/genotype, n=2 experiments. Bars represent mean ± SD. (E–G) Quantification of IL-1β (E),
IL-6 (F), and TNF-α (G) levels produced by BMDMs from WT and T300A mice at 24 hpi. (H–J)
Quantification of IL-1β (H), IL-6 (I), and TNF-α (J) mRNA levels in WT and T300A mouse
bladders 24 hpi. Bars represent mean ± SD.

Figure 4.7 Atg16l1 T300A variant does not affect canonical autophagy response to UPEC
infection: (A-B) Western blot detection of ATG16L1 and GAPDH (loading control) in whole
bladder protein before infection (A) and 24 hpi (B). (C) Western blot detection of LC3 in whole
bladder protein from fed and starved WT and T300A mice. (D) Western blot detection of LC3 in
whole bladder protein from WT and T300A mice 3 hpi. Number below the blots showing
densitometry quantification of the blots.

Figure 4.8 The presence of T300A variant differentially regulates genes coding Rab GTPases
upon UPEC infection. (A) q-PCR analysis of mRNA levels of Rab 27b, Rab 11a and Rab 33b in
bladders from WT and T300A mice before and 24 hpi. (B). Quantification of intracellular UPEC
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CFU in BECs treated with vehicle and 3-PEHPC at indicated time post infection. * P<0.05;
**P<0.01 by Mann-Whitney test.

Figure 4.9 ATG16L1 T300A variant leads to superficial cell architectural alterations in
human bladders: (A–B) H&E staining of human bladder tissue biopsies from participants
carrying ATG16L1 rs2241880 AA (A) and GG (B) alleles. Red arrow head, vesicles. (C).
Percentage of human bladders of indicated genotype that showed vesicular congestion phenotype.
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Figure 4.1: Mice carrying the Atg16l1 T300A variant exhibit reduced UPEC persistence
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Figure 4.2: Atg16l1 T300A variant mice exhibit superficial cell architectural changes
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Figure 4.3: Loss of ATG16L1 or ATG7 but not ATG14L1 or EPG5 leads to decreased
intracellular UPEC growth in BECs
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Figure 4.4.: Loss of Atg16l1 or Atg7 in urothelium but not Atg14l1 or Epg5 leads
to significant reduction in QIR formation
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Figure 4.5: Loss of Atg16l1 or Atg7 but not Atg14l1 or Epg5 leads to urothelial
architecture alterations
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Figure 4.6: Atg16l1 T300A variant does not affect cytokine response to UPEC infection
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Figure 4.7: Atg16l1 T300A variant does not affect canonical autophagy response to
UPEC infection
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Figure 4.8: The presence of T300A variant differentially regulates genes coding
Rab GTPases upon UPEC infection
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Figure 4.9: ATG16L1 T300A variant leads to superficial cell architectural
alterations in human bladders
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Chapter 5: The Decision Maker: Understanding the
role of IFRD1 in urothelial tissue plasticity
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5.1 Abstract
The bladder urothelium forms a highly specialized watertight barrier to urinary wastes. The
urothelium offers an unusual example of tissue regeneration: although urothelial cells do not
rapidly turn over under physiological conditions, they have an impressive capacity to regenerate
tissue upon injury. Even more remarkable, depending on the modality of injury (sterile, infectious)
there appear to be two distinctive modes of urothelial regeneration. We have previously shown
that in response to a urinary tract infection (UTI), the urothelial stem cell niche becomes activated
and induces rapid restoration of the urothelium, whereas, regeneration following sterile injury does
not involve stem cell activity. However, the key driver(s) of mode of regeneration choice has yet
to be elucidated.
To better understand the regulatory pathways important for tissue regenerative response,
we performed large unbiased RNA-Seq and proteomics analyses. We identified interferon-related
developmental regulator 1 (IFRD1), a transcriptional co-regulator, as a gene that is rapidly
activated upon the induction of a UTI. Ifrd1 has been shown recently to be important for
paligenosis, a process differentiated cells use to reenter the cell cycle to regenerate lost tissue.
Interestingly, we observe that even in the absence of injury, loss of Ifrd1 results in gross urothelial
defects: excess vesicular congestion in terminally differentiated cells including aberrant
accumulation of mitochondria and abnormal endoplasmic reticulum (ER). Furthermore, we show
that Ifrd1 affects localization and trafficking of uroplakins, tetraspanin proteins that constitute
organized urothelial plaques, and which dimerize in the ER and assemble into heterotetramer in
the Golgi and trans-Golgi network (TGN), where they undergo chain-specific glycosylation and
proteolytic processing. Fully formed uroplakin plaques are then expressed along the apical surface
of the urothelium where they are eventually endocytosed and undergo recycling. Loss of Ifrd1
results in dysfunctional uroplakin ER-> Golgi translocation and aberrant accumulation in ER.
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Proteomic analyses revealed a significant increase in the unfolded protein response (UPR) and
stress.
In agreement with this, we note an increase in the ER chaperone, Bip and the association
of IFRD1 with a number of eIF2α subunits, the critical translation initiation factor that quenches
global, cellular mRNA translation and can ultimately trigger apoptosis. Indeed, induction of injury
in the ifrd1-/- mouse results in massive epithelial exfoliation into the urine and dysregulated
recruitment of progenitor cells for regeneration. Ongoing work is elucidating the molecular
underpinnings of this response. In sum, we suggest IFRD1 plays a role in the decision-making
matrix of urothelial regeneration and that IFRD1 plays a role in urothelial plasticity.
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5..2 Introduction
The primary function of the bladder is the storage and release of urine. The urinary bladder
epithelium (urothelium) forms a highly specialized impermeable barrier which provides protection
of the tissue from potential toxic factors excreted in urine 1-5. The urothelium is a pseudo-stratified
transitional epithelium, with a remarkable capacity for regeneration. There are three main cell
types within the urothelium: terminally differentiated superficial cells, intermediate cells, and basal
cells of which, there are a subset of stem cells 6-8. Under homeostatic conditions, the urothelium is
quiescent and has what is believed to be the slowest turnover of any mammalian epithelia

9-11

.

However, upon injury there is the immediate activation of regenerative pathways, leading to the
complete restoration of the urothelium within 72 hours post injury

12-17

. How the urothelium

governs long-term quiescence, while rapidly activating regeneration, has yet to be discerned.
The bladder routinely undergoes distension-contraction cycles wherein the bladder can
dramatically extend its volume. This is accomplished by discoidal fusion vesicles (DFV) lined
with asymmetric unit membrane (AUM) of the four uroplakin proteins (Ia, Ib, II, and III) which
are recruited to the apical surface of the luminal superficial cells

18-22

. Upon contraction, these

uroplakin proteins are then recycled via endocytosis, multivesicular bodies (MVB) trafficking, and
degradation by lysosomes thereby decreasing the size of the urothelial membrane 23-26. Given the
number of voiding cycles the urothelium undergoes, it is process requiring extensive trafficking
and recycling of uroplakin in a single superficial cell while maintaining barrier function. Although
a number of pathways have been identified that play key roles in urothelial injury response, little
is known about pathways that regulate normal urothelial homeostasis. Given that the urothelium
is exposed to urinary wastes and must withstand shear forces from continual stretching and
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contracting, we hypothesized that the urothelium could be considered under a state of constant
stress response.
Here, we identify interferon-related developmental regulator 1 (IFRD1), ), a transcriptional
co-regulator encoded by the IFRD1 gene and shown to be involved in regeneration and stress
response to be a key player in maintaining urothelial homeostasis. IFRD1 has been shown to act
as a transcription coactivator/repressor through its interactions with transcription factors and
histone deacetylase (HDAC) complexes 27-30. More recently, IFRD1 has been identified to play a
role in a novel process called paligenosis. Paligenosis is an evolutionarily conserved program in
which differentiated cells re-enter the cell cycle following injury

31,32

. Following proliferation-

inducing injuries, pancreatic and stomach cells rapidly activate autodegradative machinery. Once
the structural and functional components have been recycled and gene expression has been altered,
re-entry into the cell cycle may occur. Similarly, the unperturbed urothelium undergoes massive
structural transitions daily, during normal voiding behaviors. In the urothelium, we demonstrate
that IFRD1 plays a role in modulating uroplakin trafficking through the endoplasmic reticulum
(ER) and Golgi and protecting the urothelial cells from stress. Loss of ifrd1 results in significant
ER stress resulting in spontaneous loss of urothelial cells. Deeper understanding of IFRD1
function may identify pathways regulating urothelial homeostasis.

5.3 Results
5.3.1 Loss of IFRD1 results in increased sloughing of urothelial cells which exhibit altered
structure
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IFRD1 has previously been shown to be activated in response to injury stimuli: for
example, in pancreatic acinar and gastric chief cells, IFRD1 is only expressed in response to
metaplasia-inducing injury

32,33

. Here, we sought to determine whether IFRD1 was activated in

response to injury in the urothelium. We note that IFRD1 is activated as early as 6 hours post
infection by uropathogenic E. coli (Figure 5.1A). It’s expression was evident as early as
embryonic day 12 (Figure 5.1B) but was reduced with age (Figure 5.1A, 0hr) . These findings
suggested IFRD1 played a role in injury response but was also potentially important for normal
development and maintenance of urothelial homeostasis.
RNA sequencing of bladders from unperturbed 8-10 week old wild-type (WT) and IFRD1
knockout (Ifrd1-/-) mice, revealed the significantly altered expression of over 300 genes (Figure
5.1C). Gene Ontology analysis indicates pathways involved in tissue differentiation, regulation of
system processes, and responses to stimuli indicating that these processes play a role in the
maintained of the uninjured bladder.
To first examine whether IFRD1 indeed played a role in normal urothelial homeostasis, we
evaluated urothelial in wild type (WT) and Ifrd1-/- mice34. Urinalysis revealed that Ifrd1-/urothelium underwent spontaneous shedding into the urine in the absence of any injury. It is rare
for urothelial cells to be shed into the urine under homeostatic conditions. Accordingly, urine
cytology samples taken from WT mice did not contain sloughed urothelial cells (Figure 5.2A).
However, Ifrd1-/- urine samples contained a number of clumped urothelial cells (Figure 5.2A)
identifiable as superficial cells. This same phenotype was also seen in our transmission electron
microscopy (TEM) images in which we captured cellular debris in the lumen of Ifrd1-/- samples
and none in WT (Figure 5.2B). Histological analysis of normal unperturbed urothelium of WT
mice, reveals 3-4 cell layers, with large often multinucleated superficial cells (Figure 5.3A). Upon
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examination of Ifrd1-/- urothelium, we observed areas in which superficial cells appeared to be
enlarged, filled with a number of vesicle-like structures (Figure 5.3B). While these vesicles are
not uncommon in WT samples, we found that the deficient superficial cells contained an
abundance of these vesicles, which may be a possible reason for the increase in cell size.
Unsurprisingly, we were also able to identify cellular debris throughout our histological sections
of the Ifrd1-/- (Figure 5.3B).
Multivesicular bodies (MVBs), also known as late endosomes, are a subset of endosomes
that encompass membrane-bound vesicles. In the bladder, MVBs are important for the trafficking
of uroplakin plaques from the apical surface of superficial cells where they are then recycled 26,35.
To investigate whether these vesicles were MVBs, we performed TEM to examine the
ultrastructure of these superficial cells. Within these superficial cells, we were able to identify a
number of structures: MVBs, fusiform vesicles, lysosomes, and mitochondria. As expected, the
MVBs of the WT superficial cells appear empty or contain amorphous material, which has been
identified as asymmetric unit membrane (AUM) structures (Figure 5.3C). Surprisingly, the MVBs
of IFRD1 KO superficial cells appear packed with AUMs along with other undigested cargo
(Figure 5.3D). While we did not observe a significant difference in the amount of MVBs, we
found that there was a significant difference in the amount of cargo-filled MVBs within the
knockout (Fig 2E). Lysosomes are acidic compartments in which cellular compartments are broken
down. Similarly, we found there to be a significant accumulation of lysosomes within the IFRD1
KO (Figure 5.3G), when compared to that of the WT (Figure 5.3F), across the given surface area
of the superficial cell (Figure 5.3H). Superficial cells notably contain a high number of
mitochondria, which was true for both the WT (Figure 5.3I) and the IFRD1 KO (Figure 5.3J).
Interestingly, we found that the IFRD1 superficial cells had significantly more mitochondria than
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the WT (Figure 5.3K), and many of these mitochondria contained large electron dense regions
that disrupt normal cristae patterning. Together, these findings indicated that IFRd1 plays a role
in maintaining urothelial tissue architecture and uroplakin trafficking.
5.3.2 Loss of Ifrd1 results in reduced expression and disorganized trafficking of uroplakin
III protein
Following the resulting accumulation of cargo filled MVBs due to the loss of IFRD1, we
next sought to understand the role of IFRD1 in uroplakin trafficking. One of the morphological
hallmarks of terminally differentiated urothelial superficial cells, are the presence of urothelial
plaques called uroplakin which accumulate along the apical surface of the superficial cell.

36-38

.

These hexagonal plaques consist of four membrane proteins, which are a part of the tetraspanin
family: uroplakin Ia (UPIa, uroplakin Ib (UPIb), uroplakin II (UPII), and uroplakin III (UPIII) 39,40.
The apical expression of UPIII within superficial cells is an important marker of terminal
differentiation. As expected, UPIII is expressed along the apical surface of WT urothelium (Figure
5.4A). However, within Ifrd1-/- superficial cells, UPIII is more diffusely expressed (Figure 5.4B).
We next quantified UPIII expression via RT-qPCR, and found that Ifrd1-/- bladders express
significantly less UPIII than WT bladders (Figure 5.4C).
To understand why uroplakin expression is disorganized in the IFRD1 KO, we next sought
to examine how uroplakin trafficking may be affected. First, uroplakins form heterodimerize in
the endoplasmic reticulum (ER) as UPIa/II and UPIb/UPIIIa 41,42. Next, they form heterotetramers
as UPIa/UPII-UPIb/UPIIIa in the Golgi and undergo proteolytic processing, and chain-specific
glycosylations in the trans-golgi network (TGN) 42. These heterotramers are then trafficked to the
apical surface of the superficial cell via the TGN-derived discoidal and fusiform vesicles

43,44

.

Based on our knowledge of the post-translation modifications the heterotramers undergo as they
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are trafficked through the ER-golgi-TGN pathways, we can track the location of uroplakins using
known sensitivities to endoglycosidases.
Consistent with published data, UPIII becomes sensitive to PNG-F following golgi
mediated complex glycan formation in both the WT and Ifrd1-/- (Figure 5.4D blot 1, lanes 1 and
3), where we see the N-linked oligosaccharide

at ~20kD and the core protein at ~28kD.

Interestingly, the Ifrd1-/- has more of the cleaved glycan while the WT has more of the core protein.
This could suggest that most of the UPIII has remained in the ER because of its failure to undergo
multiple glycosylation in the golgi; this does not happen and instead we get a buildup of
glycoproteins in the gogli. Control samples (which were not incubated with the endoglycosidases)
show the presence of both the full UPIII protein at 47kD, is present in both the WT and Ifrd1-/(Figure 5.4D blot 1, lanes 2 and 4). Because this is an ongoing process, it comes as no surprise
that we are also capturing the small amounts of the N-linked oligosaccharide at ~20kD within the
control lanes.
UPIII is insensitive to Endo-H once it has undergone full golgi-mediated complex glycan
formation. In the WT most of UPIII has undergone glycan formation, and so while you get some
cleavage (Figure 5.4D blot 2, lane 1 compared to 2), most of UPIII is in the mature protein form
(50kD). However, in the Ifrd1-/- , both the Endo-H treated and control contain equal amounts of
cleaved protein (Figure 5.4D blot 2, lanes 3 compared to 4). This would suggest UPIII in the
Ifrd1-/- has incomplete Golgi mediated complex glycan formation, and some of the protein remains
trapped in the ER. As an aside, the small band at 75kD indicates crosslinked species, and the band
at 37kD is UPIIIb. Taken together, our data suggest aberrant trafficking of uroplakin III within
Ifrd1-/- superficial cells. Notably, it appears that these proteins are becoming trapped within the
ER. Taken together, this data suggest uroplakin trafficking is altered due to the loss of Ifrd1.
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5.3.3 Altered UPIII trafficking induces the upregulation of ER chaperone protein BiP, and
the subsequent accumulation of ER within autophagosomes
Under homeostatic conditions, BiP (also known as Grp78) acts as an ER chaperone.
Following the accumulation of unfolded protein in the ER, BiP binds protein peptides, triggering
ER stress sensors 45. We first examined the expression of BiP in the unperturbed WT bladder, of
which we observed puncta throughout the superficial cells, along with normal expression of UPIII
(Figure 5.5A). In the Ifrd1-/-, we also observed puncta throughout the superficial cells, however,
we also identified BiP+ vesicles that also colocalized with UPIII (Figure 5.5A). We next assessed
the expression of BiP in bladder tissues. The upregulation of BiP in the bladders of Ifrd1-/-, was
seen at both the mRNA (Figure 5.5B) and protein level (Figure 5.5C). Because BiP is expressed
within the ER, the expression of BiP in vesicle-like structures of Ifrd1-/- tissue sections should
correlate with an accumulation ER within these same structures. Further TEM analysis of Ifrd1-/superficial cells revealed the presence of ER congested double-membrane autophagosomes
(Figure 5.5D). ER-phagy is the lysosomal degradation of ER, which includes the formation of
autophagosomes enveloped ERs 46. This observation was only noted in the bladder tissue of Ifrd1/-

mice. Together with our UPIII trafficking data, these findings suggest due to the loss of Ifrd1,

ER-trapped UPIII induces the accumulation of BiP, and the induction of ER-degradation.

5.3.4 IFRD1 knockout is unable to respond to ER stress, resulting in increased cell death and
proliferation
The accumulation of abnormal, misfolded, or unfolded protein within the ER, causes stress
to the cell and triggers a process called the unfolded protein response (UPR). UPR results in two
main outcomes: restoration of protein homeostasis (i.e cell survival), or the induction of apoptosis.
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Cell survival involves the global reprograming of gene transcription, translation, and protein
folding. If the cell is unable to offset ER stress, or chronic stress occurs, apoptosis is instead
promoted 47.
There are three UPR pathways that are triggered in response to ER stress induced BiP
accumulation: the release, homodimerization, and autophosphorylation of PERK and IRE1a, and
the translocation of ATF6 into the Golgi 48,49. Each of these pathways have different effectors and
results in either cell survival or induction of apoptosis. We performed an unbiased sequencing of
the transcriptome of WT and Ifrd1-/- mouse bladders, which revealed the down regulation of the
Ire1a and Atf6, while the expression of PERK was variable (data not shown). These finding were
surprising due to the significant upregulation of ER stress sensor, BiP. Each of the three UPR
pathways can exert negative and positive feedback, in the promotion or inhibition of cell survival.
For this reason, we next sought to understand which arm of UPR were activated.
Following the phosphorylation of PERK, global protein translation is suppressed by
phosphorylation of eIF2a, an initiation factor 50. Sustained upregulation of PERK results in the
activation of the PERK-ATF4-CHOP pathway, which triggers cell death via apoptosis 51,52. Here,
we see the significant upregulation of both ATF4 and CHOP mRNA levels in the Ifrd1 null mice
when compared to the WT (Figure 5.6A and Figure 5.6B).
Upon activation, IRE1a acts as an endonuclease and splices the transcription factor XBP1
53

. Targets of XBP1, including ER chaperones and components of endoplasmic reticulum

associated protein degradation (ERAD) such as Edem1, have been shown to essential for cell
survival

54-57

. In the Ifrd1-/- , we did not detect any significant changes in the expression of total

XPB1 (Figure 5.6C), spliced XPB1 (Figure 5.6D), or unspliced XBP1 (Figure 5.6E), by RTqPCR. Nor did we examine a significance difference in the expression of EDEM1 (Figure 5.6F).
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Taken together, our data suggest that in the absence of Ifrd1, the urothelium is unable to activate
fully activate cell survival pathways of UPR.
We hypothesized that it is the initial disorganized trafficking of UPIII in the urothelium,
that induces ER stress; which Ifrd1-/- urothelial cells cannot respond to. Proteomic analysis of
unperturbed human bladder cancer cell line 5637 was done to identify direct IFRD1 protein-toprotein interaction with components of vesicle trafficking and UPR. Using an antibody against
IFRD1 and an IgG control, we performed co-immunoprecipitation followed by tandem mass
spectrometry (MS/MS). We identified a total of 2271 proteins that interact with both IFRD1 and
the IgG control at a probability rate of over 95% (see methods for exclusion criteria). Of those
2271 protein hits, 444 interact with IgG alone, 943 with IFRD1 alone, and 884 were found to
interact with both IFRD1 and IgG. For our analysis, we focused on hits that only interacted with
IFRD1.
The 943 IFRD1-only hits were ranked using their Total Spectrum Count. For brevity, the
top 60 hits can be found in Table 5.1. Excitingly, two protein interactions directly linked IFRD1
to vesicle trafficking and regulation of UPR response: RAB11a-binding protein RELCH and
eukaryotic initiation factors (eIF). Global regulation protein translation is a crucial step in the
process of proteostasis. Initiation factors form a complex that stabilize and allow for the assembly
of ribosomes at the start of translation. During UPR, regulation of eIF has a duel role in both
activating UPR genes and global inhibition of protein production. Our proteomic analysis revealed
IFRD1 to interact with a number of initiation factor subunits along with ribosomal proteins (Table
5.1). These interactions, provide direct evidence of the role of IFRD1in regulation of UPRassociated genes.
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Once uroplakins have been adequately folded and trafficked through the ER-golgi-TGN,
they must now transported to the apical surface of the superficial cell. Uroplakin plaques begin to
take form in the post-golgi compartment, of which discoidal/fusiform vesicles (DFV) bud off and
mature as they make the way towards the apical surface 58. A group of small GTPases proteins
called RABs, are essential for the intracellular trafficking of vesicles throughout the cell and it’s
membrane 59. RAB11a and RAB27b are both involved in the trafficking of membrane bound DFVs
in superficial cells

60,61

. Our analysis revealed IFRD1 to interact directly with RAB11a-binding

protein RELCH, the highest interaction based on total spectrum count (Table 5.1). Because of the
involvement of Rab11a and Rab27b in the trafficking of uroplakin, we next examined the
expression of these. We found that the expression of both Rab11a (Figure 5.6G) and Rab27b
(Figure 5.6H) were significantly downregulated in Ifrd1-/- bladders. RELCH is also involved in
the transport of cholesterol from recycling endosomes to the TGN through interactions with
RAB11 and oxysterol-binding protein (OSBP)62. This data directly supports the role Ifrd1 in the
regulation of uroplakin trafficking.
Thus far, we’ve provided evidence in support of the loss Ifrd1 renders cells of the
urothelium unable to respond to ER stress. Instead, we see the sloughing of superficial cells due
to UPIII accumulation in the ER (Figure 5.2A). We next sought to determine whether these
superficial cells indeed experiencing increased apoptosis. TUNEL assay fluorescently labels cells
positive for double-strand DNA breaks, which are generated during apoptosis. In the unperturbed
WT bladder, we do not observe any TUNEL positive cells (Figure 5.6I). However, in our Ifrd1-/mice, we found that practically every superficial cell was positive for TUNEL (Figure 5.6I). This
observation suggest that increased sloughing of superficial cells is due to the induction of
apoptosis.
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Notably, we did not identify any clear gaps in the urothelium, which is surprising given the
number of apoptotic cells. In order to offset the loss of superficial cells, we would expect there to
be an overall increase in urothelial proliferation. To assess the proliferative index of the
urothelium, we next examined the expression of Ki67. Under homeostatic conditions, the virtually
quiescent urothelium contains few proliferatively active cells, which reside within the basal cell
compartment 11,63,64. As expected, we found that WT bladders contained a small number of Ki67positive cells (Figure 5.6J). However, within the Ifrd1-/- urothelium, we found virtually every
basal cell to be positive for Ki67 (Figure 5.6J). Taken together, this data shows that ER stress
within the superficial cells upregulates programmed cell death instead of cell survival pathways.

5.4 Discussion

The mechanisms IFRD1 uses to regulate the survival response of superficial cells appears
multifaceted. The first, IFRD1 is involved in the trafficking of uroplakin proteins. In the
urothelium, we observed the disruptive trafficking of uroplakins which are essential for the
function of superficial cells. Whether it’s due to mis-glycosylations, or lack of glycosylations,
many uroplakin proteins are entrapped within the ERs of IFRD1 KO superficial cells. Further work
needs to be done to establish where in this early stage of uroplakin trafficking, IFRD1 interacts
with these components. Following the exit from the ER-golgi-TGN, we show that IFRD1 KO
bladders have reduced expression of and IFRD1 appears to directly interact with vesicle trafficking
components Rab11a and Rab 27b. Loss of Rab 11 and Rab27 are associated with the accumulation
of late endosomes (MVBs) and lysosomes

65,66

. Similarly, in the absence of IFRD1, we see also

see the accumulation mitochondria with lipid droplets. Work from the Sun lab has shown defective
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uroplakin trafficking leads to the accumulation of uroplakin-positive lipid droplets within
mitochondria

67

. The presence of dysfunctional mitochondria would have a global impact on

superficial cell metabolism. Given the energy required for protein trafficking, it comes as no
surprise that our preliminary data suggest there is increased glycolytic flux within IFRD1 KO
urothelium (data not shown). More work needs to be down to establish the direct link of IFRD1
and protein glycosylation and whether the trafficking of other proteins are also affected.
The unfolded protein response is essential for cell survival in response to ER stress. Here,
we show that the inability of IFRD1 KO to respond to ER stress, results in increased cell death.
UPR is a step by step process by which ER stress sensors activate the global inhibition of
translation and the selective activation of UPR genes. Here, we show that while ER stress sensor,
BiP, is responsive in the absence of IFRD1, we do not see the activation of critical cell survival
pathways, instead we have the induction of apoptosis. We show the direct Our work provides a
novel role of ER stress response in the homeostatic maintenance of the bladder urothelium.
Our findings of increased urothelial sloughing and turnover in the absence of injury, is a
quite a surprising finding. Unlike in other tissues such as muscle, liver, and adipose tissues that
require an injury or stimulation; in the bladder, we have a striking phenotype in the absence of
injury

32,68,69

. What makes the bladder urothelium unique is the constantly changing urine

environment. Urine is composed of waste byproducts from the kidney filtration system. Urine
samples are a noninvasive and easily attainable source for biomarkers for a number of diseases
and conditions 70. Recent studies have revealed the presence of a urine microbiome 71-73. Given the
composition of urine, superficial must ensure barrier function as protection of the subcutaneous
tissue. Here we show that proliferative capacity of basal cells are not affected by the loss of IFRD1,
lost superficial cells are replenished by cells within the transitional epithelium. Interestingly, the
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loss of IFRD1 during metaplastic injury models in in pancreatic acinar cells and gastric chief cells
results in inhibition of the third phase of paligenosis, cell re-entry cycle

32

. Why basal and

intermediate cells of the urothelium able to proliferate in the absence of IFRD1, needs to be
discerned. One possibility is that superficial cells undergo a paligenosis-like process in which these
terminally differentiated cell repair and/or offset cellular stress through a pathways independent of
injury-induced regeneration.
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5.5 Experimental Procedures
Mice
All protocols were approved by the animal studies committee of Washington University School of
Medicine. Mice were maintained under specific pathogen-free conditions in a barrier facility,
under a strict 12h light/dark cycle. All female mice aged (18-months old) and young (10weeks
old) mice were obtained from the National Institute on Aging.

Urine cytology and Dihydroethidium ROS Assay
Urine specimens from mice were collected, and sediments were obtained by cyto-centrifuging
50uL of urine onto poly-L-lysine-coated glass slides. Slides were then stained with Papanicolaou
for the identification of sloughed superficial cells.
To assess for the production of ROS by the sloughed superficial cells, slides were incubated with
10µM dihydroethidium (ThermoFIsher Scientific, D23107) for 30 min at 37°C, rinsed in PBS, and
then mounted with Prolong Diamond Antifade Mountant with DAPI (ThermoFisher Scientific,
P36962). Sections were imaged using Zeiss Axio Imager M2 Plus Wide Field Fluorescence
Microscope.

Immunofluorescence
Following sacrifice, bladders were removed and fixed in methacarn (60% methanol, 30%
chloroform, and 10% acetic acid) for 20mins, before embedding within paraffin. Five-micron
sections were then stained with hematoxylin and eosin, and the following antibodies: BiP (Cell
Signaling, C50B12), Uroplakin III (Fitzgerald, NA), Uroplakin II (Nouvus, NBP23389) and Ki67
(Abcam, ab833. Images were taken on a Zeiss Apotome microscope at 40x magnification.
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Transmission electron microscopy (TEM) and quantification of cell structures and organelles
Whole bladders of WT and Ifrd1-/- mice were fixed using 2% glutaraldehyde and 3%
paraformaldehyde in 0.1 M sodium cacodylate. Samples were then washed a total of three times
in sodium cacodylate buffer and post-fixed in 1% osmiumtetroxide for one hour, and then stained
in 1% uranyl acetate for an hour, before being rinsed, dehydrated, and dried using critical point
drying. Bladder samples were then gold-coated and viewed using JEOL 1200 EX II Transmission
Electron Microscope. For quantification of MVB, lysosomes, and mitochondria, images of
superficial cells were taken at 2500x. The number of MVBs, cargo-containing MVBs,
mitochondria, and lysosomes were quantified, and the amounts were reported as per surface area
examined. (n= 50-150 TEM sections from four individual mice).

TUNEL
After sacrifice, mouse bladders were flash frozen using OCT. Seven-micron sections were then
stained with TUNEL according to manufactures protocol (Roche 11684795910, In Situ Cell Death
Detection Kit). Images were taken on a Zeiss Apotome microscope. (n=4 mice)

Deglycosylation assay
This protocol was adapted from Liao, et al 2019. In short, homogenized whole bladders were
digested in 0.5% SDS and 40-mM dithiothreitol and incubated at 30°C for 6-hours with
endoglycosidase H (Endo-H) and PNGase-F according to manufactures protocol (NEB, P0702S
and P0704S). Samples were then resolved on a 15% SDS-Page gel and transferred to a PVDF
membrane and blotted for anti-uroplakin antibodies.
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67

RT-qPCR
RNA was isolated from flash-frozen bladders from non-infected mice, using TRIzol (Invitrogen
15596018). Samples were then treated with DNase I (Invitrogen 18068015) to remove any
contaminating DNA. cDNA was synthesized using

SuperScript™ II Reverse Transcriptase

(Invitrogen 18064014). Expression of genes of interest were detected via RT-qPCR using
SsoAdvanced Universal SYBR Green Supermix (Bio-Rad 1725275) on a CFX96 Touch RealTime PCR Detection System (Bio-Rad). List of primers used can be found in Table 5.2. Relative
expressions were calculated using the Double Delta Ct Value, and normalized to 18S.

Western Blotting
Protein was isolated from flash-frozen mouse bladders, using TBST. Protein concentration was
calculated using ThermoScientific Peirce BCA Protein Kit (PI23277). 20ug of each protein
samples were then resolved on a 15% SDS-Page gel and transferred to a PVDF membrane and
blotted for BiP (Cell Signaling, C50B12).

Co-Immunoprecipitation and Proteomic Analysis
Dynabeads Protein A for Immunoprecipitation (ThermoFisher, 10001D) were resuspended in
PBS-Tween (0.2%)+ Protease Inhibitor, before 10min incubation with anti-IFRD1 (Abcam,
ab229720) and Rabbit IgG (Cell Signaling, 2729S). Cultured 5637 human bladder cancer cells
were lysed in Pierce IP Lysis Buffer (ThermoFisher, 87787), and incubated for 30mins at room
temperature. Following centrifugation of the lysate, the supernatant was transferred to the bead
now attached to the antibodies of interest. Beads were incubated overnight at 4C, and then gently
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washed to remove unbound proteins. Samples were then submitted to the Proteomics Core
Laboratory at Washington University in St Louis for MS/MS analysis.
For database searching, the tandem mass spectra were extracted by the search engine Mascot
(version 2.5.1). Mascot searched the UNI-HUMAN-REF-20190731 database containing 20667
entries. Mascot was searched with a fragment ion mass tolerance of 0.05.0 Da and a parent ion
tolerance of 25 parts per million. In Mascot, Carbamidomethyl of cysteine was specified as a fixed
modification; and the following were specified as variable modifications: Gln->pyro-Glu of the nterminus, deamidated of asparagine and glutamine, oxidation of methionine and acetyl of the nterminus.
Criteria for protein identification was done using Scaffold_4.11.0 Proteome Software, which
validated MS/MS based peptide and protein identifications. Identification of peptides were
accepted if established at >91.0% probability to achieve an FDR >1.0%, using the Scaffold Local
FDR algorithm. Proteins were identified and accepted if established at >66.0% probability, with
at a minimum of 1 identified peptide. Proteins probabilities were assigned using the Protein
Prophet algorithm 74. (Adapted from Scaffold_4.11.0)

RNA-Sequencing
Preparation of bladders for RNA isolation, sequencing, and data analysis were previously
described

75

. In short, bladders were snap frozen and homogenized for RNA isolation using

RNeasy Mini Kit (Qiagen, 74101). Preparation of libraries was done with Ribo-Zero rRNA
depletion kit (Illumina) and then sequenced on HiSeq3000 (Illumina). Reads were then aligned to
the Ensemble top-level assembly with STAR version 2.0.4b. Gene counts were produced from the
uniquely aligned unambiguous reads by Subread:feature Count version 1.4.5, and transcript counts
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were derived by Sailfish version 0.6.3. Using RSeQC version 2.3, sequencing performance was
determined for the total number of aligned reads, total number of uniquely aligned reads, genes
and transcripts detected, ribosomal fraction, known junction saturation and read distribution over
known gene models. All gene counts were then imported into R/Bioconductor package EdgeR and
TMM normalization size factors were calculated to adjust samples for differences in library size.
Some features, such as ribosomal and any feature not expressed in at least three samples, were
were excluded from further analysis and TMM size factors were recalculated to create effective
TMM size factors. These factors and matrix counts were then imported into R/Bioconductor
package Limma, and the voomWithQualityWeights function was used to calculate the observed
mean-variance relationship of every gene/transcript and sample. Generalized linear models were
then used to test for gene/transcript level differential expression, which were filtered for False
Discovery Rate (FDR)-adjusted p-values less than or equal to 0.05. Adapted from Ligon et al
(2020) and Wang et al (unpublished 2021).

Statistical Analysis
For time-course experiments, two-way ANOVAs with matching were used with Bonferroni posttests for individual time points. To determine significance between two samples, unpaired t-tests,
paired t-tests, or non-parametric Mann-Whitney U tests were performed by using Graph Prism
software. P < 0.05 was used as the cut off for statistical significance. To determine significance
between treatment groups using RT-qPCR, unpaired t-test was performed using Graph Prism
software.
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5.7 Figure Legends and Figures
Figure 5.1: Ifrd1 expression in response to UPEC infection, bladder development, and the
global transcriptomic changes in bladders of WT vs Ifrd1-/- mice
A) RNA sequencing analysis, Log2 counts per million of bladder IFRD1 expression 0-24 hours
post UPEC infection in young (8-10 weeks-old) and aged (18 months-old) mice. N=4-5
bladders/time period. B) Raw counts per million expression of IFRD1 during bladder
development, beginning at embryonic (E) day 12, ending at post-natal (P) day 5. C) Heatmap of
global tissue transcriptome of WT and Ifrd1-/- bladders with a fold-change >2 and BenjaminiHochberg FDR-adjusted P<0.05. Total bladders n=8.

Figure 5.2: Loss of IFRD1 results in increased urothelial turnover in the unperturbed
bladder
A) Urine cytology from WT and Ifrd1-/- mice, showing a number of sloughed superficial cells
within the KO. Magnification 60x n=4 B) Transmission electron microscopy depicting the edge
of a superficial along with the lumen of WT and Ifrd1-/-. Cellular debris is only observed in the
samples of the Ifrd1-/-. Magnification 2500x and 6000x n=4

Figure 5.3: IFD1 KO mice display gross urothelial defects and altered superficial cell
ultrastructure
A) Urothelium histology of WT and (B) Ifrd1-/-. Black arrow depicting multivesicular bodies
(MVB), which has accumulated in the KO. C) Transmission electron microscopy of WT and (D)
Ifrd1-/- superficial cells, with MVB denoted by arrows. MVB within the Ifrd1-/- contain a
accumulation of un-digested material. Quantification of cargo-filled MVB per square area of the
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superficial cell (E). Lysosomes within (F)WT and (G) Ifrd1-/- superficial cells, quantification of
lysosomes per square area (H). Mitochondria of WT (I) and Ifrd1-/- (J) superficial cells,
quantification of mitochondria per square area of the superficial cell. Notably, mitochondria of the
KO have electron dense regions within the cristae. Magnification at 2500x and 15000x. n=4

Figure 5.4: Loss of Ifrd1 results in reduced expression and disorganized trafficking of
uroplakin proteins in the superficial cell
A,B) Immunofluorescent images of WT and Ifrd1-/- urothelium showing dispersed expression of
UPIII (green; DAPI, blue ) throughout the superficial cell of the knockout, compared to apical
expression of the WT. Scale Bar =50um C) RT-qPCR of WT vs Ifrd1-/- bladders, decreased
expression of UPIII in the knockout. D) Glycosylation assay of WT and Ifrd1-/- bladders following
incubation with the following endoglycosidases and blotting for uroplakin: blot 1) PNG-F, UPIII;
blot 2) Endo-H, UPIII. Lanes 1 and 2 are WT samples, and lanes 3 and 4 are Ifrd1-/-. n=2.

Figure 5.5: Ifrd1 deficiency leads to increased BiP expression and colocalization with UPIII,
and the accumulation of ERs within autophagosomes
A) Immunofluorescences of WT and Ifrd1-/- urothelium depicting BiP-positive (red) vesicles in
the Ifrd1-/- , which colocalizes with UPIII (DAPI, blue; UPIII, green). Scale bar=50um. B) RTqPCR and C) western blot analysis of WT vs Ifrd1-/- bladders reveals and upregulation of BiP
(n=6-10). D)TEM of accumulation of intravesicular endoplasmic reticulum in IFRD1 KO
superficial cells. Image taken at 50,000x
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Figure 5.6: Loss of Ifrd1 renders the urothelium unable to respond to ER stress, thus
inducing apoptosis
A-H) RT-qPCR analysis of downstream targets of IRE1 pathway in WT vs. Ifrd1-/- bladders. The
expression of A) ATF4 and B) CHOP are significantly upregulated, while the expression of C)
total XBP1, D) spliced-XBP1, E) unspliced-XBP1, F) EDEM1 remain unchanged, G,H) and
downregulated RAB11a and RAB27b in WT and Ifrd1-/- bladders ( n= 6-10). I) TUNEL staining
of WT and Ifrd1-/- urothelium. Every superficial cell of the knockout is positive for TUNEL
(green; DAPI in blue). White line denotes stroma. J) Ki67 (red; DAPI in blue, ECAD in green)
immunofluorescent staining reveals only a few positive basal cells within the WT, while almost
every basal is positive in the Ifrd1-/-. Image taken at 40x RT-qPCR,
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Figure 5.1: Ifrd1 expression in response to UPEC infection, bladder development, and the
global transcriptomic changes in bladders of WT vs Ifrd1-/- mice
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Figure 5.2: Ifrd1-/- mice have increased urothelial cell sloughing
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Figure 5.3: Ifrd1-/- mice display gross urothelial defects and
altered superficial cell ultrastructure
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Figure 5.4: Loss of Ifrd1 results in reduced expression and disorganized trafficking
of uroplakin proteins in the superficial cell
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Figure 5.5: Superficial cells of Ifrd1-/- mice display an accumulation
of BiP and colocalization with UPIII
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Figure 5.6: Loss of Ifrd1 renders the urothelium unable to respond the ER stress,
thus inducing apoptosis
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Table 5.1 List of top 60 proteins that interact exclusively with IFRD1
Protein and Gene Name
RAB11-binding protein RELCH

160

Total Spectrum Count

Actin, cytoplasmic 1

117

ATP-dependent RNA helicase DDX3Y

88

BTB/POZ domain-containing protein KCTD12

66

Interferon-related developmental regulator 1

61

Tyrosine-protein phosphatase non-receptor type 13

44

Trinucleotide repeat-containing gene 6B protein

42

Tyrosine-protein phosphatase non-receptor type 3

41

WD repeat-containing protein 13

41

40S ribosomal protein S4, Y isoform 1

40

Probable helicase with zinc finger domain

35

Zinc finger and BTB domain-containing protein 2

35

Cold shock domain-containing protein E1

34

DNA topoisomerase 3-beta-1

33

Eukaryotic translation initiation factor 4 gamma 3

32

AP-2 complex subunit alpha-2

31

Double-stranded RNA-binding protein Staufen homolog 2

31

E3 ubiquitin-protein ligase HERC2

31

Keratin, type I cytoskeletal 15

31

WD repeat and coiled-coil-containing protein

31

Sickle tail protein homolog

30

Tudor domain-containing protein 3

30

Telomerase-binding protein EST1A

29

AP-2 complex subunit beta

28

Lysine-specific demethylase RSBN1L

28

RNA-binding protein 6

28

Protein argonaute-1

27

Epidermal growth factor receptor substrate 15

26

5'-3' exoribonuclease 1

25

ELAV-like protein 2

25

YTH domain-containing family protein 3

25

3'-5' RNA helicase YTHDC2

23

Regulator of nonsense transcripts 2

23

AP-2 complex subunit alpha-1

22

Constitutive coactivator of PPAR-gamma-like protein 2

22

Pleckstrin homology domain-containing family A member 5

22

Partitioning defective 3 homolog

20

Lysine-specific demethylase 9

19

Probable ATP-dependent RNA helicase DDX23

19
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Table 5.1 continued
RNA polymerase II-associated protein 3

19

Transcriptional activator protein Pur-beta

19

Zinc finger CCHC domain-containing protein 3

19

Aspartyl/asparaginyl beta-hydroxylase

18

MAP7 domain-containing protein 1

18

Chromodomain-helicase-DNA-binding protein 1

17

Kinesin-like protein KIF1C

17

La-related protein 4B

17

Protein FAM98B

17

Zinc finger CCCH domain-containing protein 7B

17

AP-2 complex subunit mu

16

Dynein light chain 2, cytoplasmic

16

Putative ATP-dependent RNA helicase DHX57

16

Zinc finger protein 638

16

Eukaryotic translation initiation factor 3 subunit B

15

Eukaryotic translation initiation factor 3 subunit G

15

Protein FAM91A1

15

Unconventional prefoldin RPB5 interactor 1

15

Zinc finger CCCH domain-containing protein 18

15

Centrosomal protein of 44 kDa

14

151

Table 5.2 Primer sequences used in qPCR analysis

Gene Name
sXBP1

Forward Primer (5'-3')
CTGAGTCCGAATCAGGTGCAG

Reverse Primer (5'-3')
GTCCATGGGAAGATGTTCTGG

usXBP1
Total XBP1
ATF4
CHOP
BiP

CAGCACTCAGACTATGTGCA
TGGCCGGGTCTGCTGAGTCCG
GGGTTCTGTCTTCCACTCCA
CCACCACACCTGAAAGCAGAA
TTCAGCCAATTATCAGCAAACT
CT
CTACCTGCGAAGAGGCCG
AGGAGCGGTACAGGGCTATAA
TCGGGAAAAACGTGTGGTTTA

GTCCATGGGAAGATGTTCTGG
GTCCATGGGAAGATGTTCTGG
AAGCAGCAGAGTCAGGCTTTC
AGGTGAAAGGCAGGGACTCA
TTTTCTGATGTATCCTCTTCACCA
GT
GTTCATGAGCTGCCCACTGA
ATGTGAGATGCTTAGCAATGTCA
TTCAAGAAGCTCTGTTGACTGG

EDEM1
RAB11a
RAB27b
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Chapter 6: Conclusions and Future Directions
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6.1 Conclusion
The work described here focuses on urothelial dynamics and plasticity in the injured and
uninjured state. Unlike any other organ, the bladder is under a constant state of change; undergoing
cycles of complete cellular remodeling multiple times a day during regular voiding behaviors. And
upon injury, rapidly activating regenerative signals within hours of damage. In this thesis, I
presented key processes and pathways important for urothelial homeostasis and regeneration.
In Chapter 2, I highlighted the use of murine void spot assays (VSA) in the study of lower
urinary tract symptoms (LUTS). As we age, the prevalence of LUTS such as overactive bladder,
increases. VSA consist of measuring the quantity, size and spatial distribution of individual mouse
voids across a filter paper over a given amount of time. This assays serves as an an inexpensive,
easy, and noninvasive tool to study the effects various variables on bladder 1,2.
Chapter 3, we examined the effects of vaginal estrogen therapy (VET) on age-associated
recurring UTIs and bladder inflammation. Here, we showed aged (18-months old) mice display
significantly increased reoccurring urinary tract infections (rUTIs), enhanced bacterial reservoirs,
and a robust immune response when compared to young (7-10 weeks old) mice. Furthermore,
ovariectomizing aged mice did not significantly alter UTI pathogenesis. VET, administered in a
similar regiment as post-menopausal women, significantly reduced the number of rUTIs and
upregulated restoration of the urothelium following infection. Estrogen therapy also reversed ageassociated upregulation of inflammatory pathways. The size and quantity of bladder tertiary
lymphoid tissues (bTLTs), which are found only in the aged bladder3, were also significantly
reduced by VET.
In Chapter 4, we showed that the Thr300Ala (T300A) variant of the protein encoded by
the gene ATG16L1, provides protection against UTIs. Mice carrying the T300A variant displayed
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urothelial cellular abnormalities and limited establishment of persistent intracellular bacterial
reservoirs. This was found to be due in part by the increased expression of small Rab GTPase
Rab33b, which is important for the expulsion of intracellular bacteria from the urothelium. 4
Lastly, in Chapter 5, we investigated the role of the gene Ifrd1 in urothelial plasticity. Here,
we showed that unlike any other organ under homeostasis, the loss of Ifrd1 in the bladder displayed
a remarked phenotype. Independent of injury, the urothelium of these animals presented gross
urothelial defects such as vesicular congestion, defective mitochondrial accumulation, and
increased superficial cell sloughing and turnover. The altered trafficking of uroplakin protein III
in the superficial cells of Ifrd1-/- and subsequent activation of the unfolded protein response (UPR),
revealed a novel function of the ER stress response in the homeostatic maintenance of the bladder.

6.2 Future Directions

6.2.1 Bladder specific, targeted estrogen therapy
VET has long been used as a treatment for rUTIs in post-menopausal women5-7. However,
the mechanism of action has yet to be discerned. Previously, we have shown in a clinical trial that
post-menopausal women on VET are associated with reduced rUTIs, urothelial cell sloughing, and
reduced IL-6

8

. Here, we provided evidence of VET directly improving the immune

microenvironment of the aged bladder. Aside from altered response to injury, the aged bladder has
been shown to undergo changes in the tissue resident immune cell population, such as the presence
of bTLTs3. While the formation of the bTLTs is still not fully understood, two bTLT-causing
factors TNFa and CXCL13 were found to be reduced following VET. Further investigation into
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the interactions of 17b-estradiol (E2) and these two factors would provide further evidence and
support for the use of this therapy in the treatment of bTLTs in humans.
Estrogen provides hormonal maintenance and regulation of a number of systems such as
reproductive tissue, musculoskeletal, immune, cardiovascular, and the central nervous systems 9.
The metabolite E2 produced by the body, primarily signals through two major estrogen receptors
(ER), ERa and ERb. Selective E2 signaling occurs through the balance of receptor types, within
targeted tissue. The distribution of these receptors across tissue types, along with receptor specific
knockdowns, provides insights to differences in biological and physiological functions.
Interestingly, ERa null mice are infertile, while female ERb knockout mice have reduced fertility
and males fertility is unaffected 10-12. The proliferative effects of estrogen in hormone replacement
therapy is thought to be associated with ERa rather than ERb13. In the future, to further study the
role of targeted estrogen therapy for the treatment of rUTI in post-menopausal women, the use of
specific ERb agonist can be used to specifically target the bladder. ERb is not only expressed in
the bladder, but it is highly expressed by CK5-positive basal cells.

6.2.2 Bladder organoids, a novel in vitro tool to study bladder morphology
Organoids are 3D multicellular tissue cultures that mimic the in vivo tissue. Unlike 2D
cultures, organoid culturing methods activate cells innate self-organizing capabilities, which allow
cells to form 3D spheroid-like structures. These culturing systems have greatly expanded our
ability to better model the architecture and physiology of organs, in vitro. 14,15
The bladder consist of a transitional epithelium, with a varying number of cell layers
(depending on the species), and three distinct cell types. Due to these complexities, current in vitro
modeling of the urothelium has many limitations. Using an adapted protocol from the Vivek Arora
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lab16, we’ve shown that bladder organoids can express markers of both basal and terminally
differentiated superficial cells (CK5 and UPIII respectively; Figure 6.1A). One of the key benefits
organoids have over 2D cultures, is that they recapitulate 3D tissue structure. We found that Ifrd1/-

bladder organoids recapitulate key morphological defects found in vivo. The urothelium of Ifrd1-

/-

mice appears enlarged due to the abnormal superficial cells. Our knockout bladder organoids

appear recapitulate this phenotype in overall size, when compared to WT organoids (Figure 6.1B).
The same is true for the accumulation of lysosomes, as seen by the use of live cell dye LysoTracker
(Figure 6.1C). Transmission electron microscopy also revealed the accumulation of defective
mitochondria in the cells of Ifrd1-/- bladder organoids (Figure 6.1D). Taken together, organoid
cultures offer a unique tool for the study of morphological changes in the bladder.
We can use bladder organoids as a tool for techniques that are either cumbersome, costly,
or ineffective in vivo. For example, our RNA-sequencing analysis revealed a number of key
metabolic modulators as being dysregulated with loss of Ifrd1. While there have been many recent
advancements in tissue metabolomic analysis, tissue heterogeneity and data fidelity remain a
constant challenge17-19. We performed metabolomic analysis using our bladder organoids, and
preliminary analysis of WT vs. Ifrd1-/- organoids revealed significantly altered metabolomic flux.
In the future, bladder organoids could be used to better understand how metabolic changes of
superficial cells and the urothelium as a whole, underlie the maintenance of long-term urothelial
quiescence, and the role of Ifrd1.

6.2.3 The role of IFRD1 in injury response
Our work in Chapter 5 revealed increased urothelial cell turnover in the unperturbed Ifrd1/-

bladder, which we’ve linked to the inability of the urothelium to respond to ER stress. Ifrd1 had
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previously been identified as stress response gene and involved in regeneration in a number of
tissues20-22. In this thesis, we proposed that under homeostasis, which is typically thought of as a
non-active state, the bladder urothelium is actually quite actively maintaining urothelial
quiescence. Here, we identified the ER stress response and the gene Ifrd1 as a novel regulator of
this process. We hypothesis that the urothelium is constitutively active; maintenance of barrier
function is tightly regulated and involves a number of process, along with huge morphological
remodeling that occurs rapidly and constantly with voiding behavior. While all of this occurs
during homeostasis, we can use injury models to better understand the underlaying mechanism of
the role of Ifrd1.
Following the Crispr knockdown of Ifrd1 in 5637 bladder cells (Figure 6.2A), we used
two modalities of in vitro injury, infectious and chemical(Figure 6.2B). Infection of WT and
knockout 5637 cells with UPEC resulted in increased intracellular CFUs (Figure 6.2C), 3 hours
post injury (hpi). These results are consistent with the reduced expression of Rab 11a and Rab27b
in the unperturbed bladder. Rab 11a and Rab27b are not only involved in the trafficking of
uroplakin proteins, but they are also involved in the expulsion of UPEC-containing vesicles23. In
vivo UPEC infection studies have not shown a difference in infection pathogenesis between WT
and Ifrd1-/- animals (CFU data not shown). Future studies should examine whether Ifrd1-/- bladder
show t enhanced quiescent intracellular reservoir formation due to decreased exocytosis.
Furthermore, analysis of urothelial regeneration following UPEC infection should examine
whether due to increased urothelial cell turnover at baseline, primes the Ifrd1-/- urothelium for
cellular exfoliation during infection, and regeneration. Thus, loss of Ifrd1-/- may be protective
against UTIs.
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To examine further study the role of Ifrd1 in ER stress response in the bladder, we
chemically induced ER stress using 2ug/mL tunicamycin (TN), which was first identified as an
antibiotic and works by inhibiting N-linked glycosylation, thus inducing protein accumulation
within the ER24-26. Cell cytotoxicity assay revealed that by 6 hours post treatment, over 40% of
Ifrd1-/- cells were dead, while programmed cell death was induced in only 20% of WT cells (Figure
6.2D). Given the role of Ifrd1 in the regulation of mTORC1 in stage two of paligenosis21, and the
apparent defective autophagy seen in Ifrd1-/- superficial cells at baseline, we next wanted to
examine whether autophagy activation via rapamycin treatment, would rescue the Ifrd1-/- cells
before TN treatment. Pretreatment with rapamycin before TN injury, reduced cell death of Ifrd1-/cells to comparable levels with WT cells (Figure 6.2E).
As an inducer of ER stress, and therefore UPR, we next assessed BiP accumulation
following TN treatment. Assessment of BiP accumulation in WT cells revealed significant
induction beginning at 6 hours following TN treatment, and is sustained through 24 hours (Figure
6.2F). Unsurprising, we found that within 1 hour of TN treatment, the accumulation of BiP is
already higher in Ifrd1-/- cells compared to WT (Figure 6.2F). The addition of rapamycin delayed
BiP accumulation in both WT and Ifrd1-/- cells, although BiP accumulation was still higher in
Ifrd1-/- cells (Figure 6.2G).
Lastly, we further assessed transcriptional activation of UPR pathway following induction
of ER stress by TN with and without rapamycin. Similar to protein quantification, mRNA levels
of BiP were higher in Ifrd1-/- cells compared to WT, however rapamycin treatment reversed this;
Ifrd1-/- cells had higher BiP transcripts than WT (Figure 6.2H). This pattern was the same for
both ATF4 (Figure 6.2I) and CHOP (Figure 6.2J). Accumulation of BiP results in the cleavage
of mRNA encoding XBP1. Spliced XBP-1 translocates into the nucleus, leading to the induction
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of genes involved in ERAD27. Transcript levels of total XBP1 in WT and Ifrd1-/- cells both decrease
and increase following TN treatment, however the addition of rapamycin increases total XBP1
(Figure 6.2K). As expected, spliced-XBP1 levels increased in both WT and Ifrd1-/- cells, with WT
cells having even higher levels following rapamycin treatment (Figure 6.2L). Finally, there is an
overall decrease in the levels of unspliced-XPB1 in both WT and Ifrd1-/- cells (Figure 6.2M). We
see an increase in unspliced-XBP1 transcript following the addition of rapamycin (Figure 6.2M).
Our preliminary results suggest the induction of autophagy through rapamycin treatment,
appears to rescue the ability of Ifrd1-/- cells to respond to ER stress. This suggest autophagy may
in fact play an important underlaying role in the general maintenance and overall ability to respond
to low grade stress, in the bladder. Based on our in vitro studies, it would be interesting to test
whether sustained rapamycin treatment in vivo, would repair/rescue our gross urothelial defects.
Future studies can apply our knowledge of paligenosis, to understand whether urothelium uses
similar process/machinery to maintain active urothelial homeostasis.

160

6.3 References
1
2

3
4
5
6
7
8

9
10
11
12
13
14

Fashemi, B. E. & Mysorekar, I. U. Reflections on the void: the art of micturition analysis.
American
Journal
of
Physiology-Renal
Physiology
315,
F1446-F1448,
doi:10.1152/ajprenal.00469.2018 (2018).
Hill, W. G., Zeidel, M. L., Bjorling, D. E. & Vezina, C. M. Void spot assay:
recommendations on the use of a simple micturition assay for mice. American Journal of
Physiology-Renal Physiology 315, F1422-F1429, doi:10.1152/ajprenal.00350.2018
(2018).
Ligon, M. M. et al. Single cell and tissue-transcriptomic analysis of murine bladders
reveals age- and TNFα-dependent but microbiota-independent tertiary lymphoid tissue
formation. Mucosal Immunol 13, 908-918, doi:10.1038/s41385-020-0290-x (2020).
Wang, C. et al. A non-canonical autophagy-dependent role of the ATG16L1(T300A)
variant in urothelial vesicular trafficking and uropathogenic Escherichia coli persistence.
Autophagy 15, 527-542, doi:10.1080/15548627.2018.1535290 (2019).
Anger, J. et al. Recurrent Uncomplicated Urinary Tract Infections in Women:
AUA/CUA/SUFU
Guideline.
Journal
of
Urology
202,
282-289,
doi:doi:10.1097/JU.0000000000000296 (2019).
Brubaker, L., Carberry, C., Nardos, R., Carter-Brooks, C. & Lowder, J. L. American
Urogynecologic Society Best-Practice Statement: Recurrent Urinary Tract Infection in
Adult Women. Female Pelvic Medicine & Reconstructive Surgery 24 (2018).
Raz, R. & Stamm, W. E. A controlled trial of intravaginal estriol in postmenopausal women
with recurrent urinary tract infections. N Engl J Med 329, 753-756,
doi:10.1056/nejm199309093291102 (1993).
Meister, M. R., Wang, C., Lowder, J. L. & Mysorekar, I. U. Vaginal Estrogen Therapy Is
Associated With Decreased Inflammatory Response in Postmenopausal Women With
Recurrent Urinary Tract Infections. Female Pelvic Med Reconstr Surg 27, e39-e44,
doi:10.1097/spv.0000000000000790 (2021).
Gustafsson, J.-Å. What pharmacologists can learn from recent advances in estrogen
signalling.
Trends
in
Pharmacological
Sciences
24,
479-485,
doi:https://doi.org/10.1016/S0165-6147(03)00229-3 (2003).
Chen, M. et al. Defects of prostate development and reproductive system in the estrogen
receptor-alpha null male mice. Endocrinology 150, 251-259, doi:10.1210/en.2008-0044
(2009).
Chen, M. et al. Generation and characterization of a complete null estrogen receptor alpha
mouse using Cre/LoxP technology. Mol Cell Biochem 321, 145-153, doi:10.1007/s11010008-9928-9 (2009).
Jayachandran, M. et al. Loss of estrogen receptor beta decreases mitochondrial energetic
potential and increases thrombogenicity of platelets in aged female mice. Age (Dordr) 32,
109-121, doi:10.1007/s11357-009-9119-y (2010).
Paruthiyil, S. et al. Estrogen receptor beta inhibits human breast cancer cell proliferation
and tumor formation by causing a G2 cell cycle arrest. Cancer Res 64, 423-428,
doi:10.1158/0008-5472.can-03-2446 (2004).
Kim, J., Koo, B.-K. & Knoblich, J. A. Human organoids: model systems for human biology
and medicine. Nature Reviews Molecular Cell Biology 21, 571-584, doi:10.1038/s41580020-0259-3 (2020).

161

15
16
17
18
19
20

21
22
23
24
25
26
27

Hofer, M. & Lutolf, M. P. Engineering organoids. Nature Reviews Materials 6, 402-420,
doi:10.1038/s41578-021-00279-y (2021).
Halstead, A. M. et al. Bladder-cancer-associated mutations in RXRA activate peroxisome
proliferator-activated receptors to drive urothelial proliferation. Elife 6, e30862,
doi:10.7554/eLife.30862 (2017).
Saoi, M. & Britz-McKibbin, P. New Advances in Tissue Metabolomics: A Review.
Metabolites 11, doi:10.3390/metabo11100672 (2021).
Chen, Z. et al. Combined Metabolomic Analysis of Plasma and Tissue Reveals a
Prognostic Risk Score System and Metabolic Dysregulation in Esophageal Squamous Cell
Carcinoma. Front Oncol 10, 1545-1545, doi:10.3389/fonc.2020.01545 (2020).
Beltran, A. et al. Assessment of Compatibility between Extraction Methods for NMR- and
LC/MS-Based
Metabolomics.
Analytical
Chemistry
84,
5838-5844,
doi:10.1021/ac3005567 (2012).
Micheli, L. et al. <em>PC4/Tis7/IFRD1</em> Stimulates Skeletal Muscle Regeneration
and Is Involved in Myoblast Differentiation as a Regulator of MyoD and NF-&#x3ba;B
*<sup>
</sup>. Journal of Biological Chemistry 286, 5691-5707,
doi:10.1074/jbc.M110.162842 (2011).
Miao, Z.-F. et al. A Dedicated Evolutionarily Conserved Molecular Network Licenses
Differentiated Cells to Return to the Cell Cycle. Developmental Cell 55, 178-194.e177,
doi:https://doi.org/10.1016/j.devcel.2020.07.005 (2020).
Zhao, C., Datta, S., Mandal, P., Xu, S. & Hamilton, T. Stress-sensitive Regulation of
IFRD1 mRNA Decay Is Mediated by an Upstream Open Reading Frame *<sup></sup>.
Journal of Biological Chemistry 285, 8552-8562, doi:10.1074/jbc.M109.070920 (2010).
Miao, Y. et al. Collaboration between Distinct Rab Small GTPase Trafficking Circuits
Mediates Bacterial Clearance from the Bladder Epithelium. Cell Host Microbe 22, 330342.e334, doi:10.1016/j.chom.2017.08.002 (2017).
Hakulinen, J. K. et al. MraY-antibiotic complex reveals details of tunicamycin mode of
action. Nat Chem Biol 13, 265-267, doi:10.1038/nchembio.2270 (2017).
Yoo, J. et al. GlcNAc-1-P-transferase–tunicamycin complex structure reveals basis for
inhibition of N-glycosylation. Nature Structural & Molecular Biology 25, 217-224,
doi:10.1038/s41594-018-0031-y (2018).
Surani, M. A. Glycoprotein synthesis and inhibition of glycosylation by tunicamycin in
preimplantation mouse embryos: compaction and trophoblast adhesion. Cell 18, 217-227,
doi:10.1016/0092-8674(79)90370-2 (1979).
Janssens, S., Pulendran, B. & Lambrecht, B. N. Emerging functions of the unfolded protein
response in immunity. Nature Immunology 15, 910-919, doi:10.1038/ni.2991 (2014).

162

6.4 Figure Legends

Figure 6.1: Establishment of bladder organoid culture recapitulates key morphological
phenotypes
A) Bladder organoids harvested from 10-weeks old WT female mice. Organoids were grown for
10 days before embedding. Immunofluorescence depicting CK5-positive (green) cells and UPIIIpositive (purple) cells. Images taken at 40X. B) Brightfield images of bladder organoids grown for
10 days from 10-weeks old WT and Ifrd1-/- female mice. Images taken at 40x. Scale bar=100um
C) Bladder organoids treated with LysoTracker which stains intracellular acidic compartments.
White arrows denote positive (red) acidic compartments, suggesting an accumulation of lysosomes
in the Ifrd1-/- organoids. Scale bar=100um D) TEM of bladder organoids WT and Ifrd1-/- depicting
an accumulation of lipid droplets within mitochondria of Ifrd1-/- cells. Images taken at 6000x, scale
bar=2um.

Figure 6.2: Ifrd1-/- bladder cell line displays increased response to infectious and chemical
injury
A) Crispr knockdown of IFRD1 in human bladder epithelial cell line. Western protein blot
depicting reduced IFRD1 in knockout line compared to WT lines. B) In vitro injury schematic,
UPEC infection and chemical injury caused by tunicamycin. C) Intracellular CFUs of WT and
Ifrd1-/- cells infected with UTI89 at a multiplicity of infection of 100 for 1 and 3hpi. D) Percentage
of cytotoxic WT and Ifrd1-/- cells following 2ug/mL of tunicamycin for 1-24h post injury. E)
Percentage of cytotoxic WT and Ifrd1-/- cells pre-treated for 24h with 100nM of rapamycin,
followed by 2ug/mL of tunicamycin for 1-24h post injury. F, G) Accumulation of BiP protein after
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tunicamycin treatment and protein quantification; with rapamycin. RT-qPCR WT vs Ifrd1-/- cells
following tunicamycin treatment with and without the addition of rapamycin, respectively: BiP(
H), ATF4 (I), CHOP (J), total XBP1 (K), spliced-XBP1(L), and unspliced-XBP1 (M). Cytoxicity
assay data from two rounds of experiments. Western blots and RT-qPCR analysis consist of one
round of experiments.
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Figure 6.1: Establishment of bladder ogranoid culture recapitulates
key morphological phenotypes
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Figure 6.2: Ifrd1-/- bladder cell line displays increased response to infectious and chemical injury
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